2024N46 Esito valutazione titoli

Array ( [field_titolo_frontend_all] => Array ( [#theme] => field [#weight] => -4 [#title] => Titolo frontend [#access] => 1 [#label_display] => above [#view_mode] => teaser [#language] => und [#field_name] => field_titolo_frontend_all [#field_type] => text_long [#field_translatable] => 0 [#entity_type] => node [#bundle] => allegato [#object] => stdClass Object ( [vid] => 451952 [uid] => 4 [title] => 2024N46 Esito valutazione titoli [log] => [status] => 1 [comment] => 0 [promote] => 1 [sticky] => 0 [nid] => 108442 [type] => allegato [language] => it [created] => 1710152468 [changed] => 1710152468 [tnid] => 0 [translate] => 0 [revision_timestamp] => 1710152468 [revision_uid] => 4 [taxonomy_vocabulary_2] => Array ( ) [taxonomy_vocabulary_8] => Array ( ) [body] => Array ( ) [field_titolo_frontend_all] => Array ( [und] => Array ( [0] => Array ( [value] => Esito valutazione titoli [format] => [safe_value] => Esito valutazione titoli ) ) ) [field_allegato_file] => Array ( [und] => Array ( [0] => Array ( [fid] => 128185 [uid] => 4 [filename] => 24 Selezione 2024N6 valutazione titoli web.pdf [uri] => public://2024/24 Selezione 2024N6 valutazione titoli web.pdf [filemime] => application/pdf [filesize] => 182795 [status] => 1 [timestamp] => 1710152464 [type] => document [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2614 ) ) ) [metadata] => Array ( ) [display] => 1 [description] => ) ) ) [name] => simonetta.capparotto [picture] => 0 [data] => a:2:{s:13:"form_build_id";s:37:"form-fe5ebd9e5e240c4294455b6b42fa6a76";s:14:"wysiwyg_status";a:1:{i:1;i:1;}} [num_revisions] => 1 [current_revision_id] => 451952 [is_current] => 1 [is_pending] => [revision_moderation] => [entity_view_prepared] => 1 ) [#items] => Array ( [0] => Array ( [value] => Esito valutazione titoli [format] => [safe_value] => Esito valutazione titoli ) ) [#formatter] => text_default [0] => Array ( [#markup] => Esito valutazione titoli ) ) [field_allegato_file] => Array ( [#theme] => field [#weight] => -3 [#title] => File [#access] => 1 [#label_display] => above [#view_mode] => teaser [#language] => und [#field_name] => field_allegato_file [#field_type] => file [#field_translatable] => 0 [#entity_type] => node [#bundle] => allegato [#object] => stdClass Object ( [vid] => 451952 [uid] => 4 [title] => 2024N46 Esito valutazione titoli [log] => [status] => 1 [comment] => 0 [promote] => 1 [sticky] => 0 [nid] => 108442 [type] => allegato [language] => it [created] => 1710152468 [changed] => 1710152468 [tnid] => 0 [translate] => 0 [revision_timestamp] => 1710152468 [revision_uid] => 4 [taxonomy_vocabulary_2] => Array ( ) [taxonomy_vocabulary_8] => Array ( ) [body] => Array ( ) [field_titolo_frontend_all] => Array ( [und] => Array ( [0] => Array ( [value] => Esito valutazione titoli [format] => [safe_value] => Esito valutazione titoli ) ) ) [field_allegato_file] => Array ( [und] => Array ( [0] => Array ( [fid] => 128185 [uid] => 4 [filename] => 24 Selezione 2024N6 valutazione titoli web.pdf [uri] => public://2024/24 Selezione 2024N6 valutazione titoli web.pdf [filemime] => application/pdf [filesize] => 182795 [status] => 1 [timestamp] => 1710152464 [type] => document [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2614 ) ) ) [metadata] => Array ( ) [display] => 1 [description] => ) ) ) [name] => simonetta.capparotto [picture] => 0 [data] => a:2:{s:13:"form_build_id";s:37:"form-fe5ebd9e5e240c4294455b6b42fa6a76";s:14:"wysiwyg_status";a:1:{i:1;i:1;}} [num_revisions] => 1 [current_revision_id] => 451952 [is_current] => 1 [is_pending] => [revision_moderation] => [entity_view_prepared] => 1 ) [#items] => Array ( [0] => Array ( [fid] => 128185 [uid] => 4 [filename] => 24 Selezione 2024N6 valutazione titoli web.pdf [uri] => public://2024/24 Selezione 2024N6 valutazione titoli web.pdf [filemime] => application/pdf [filesize] => 182795 [status] => 1 [timestamp] => 1710152464 [type] => document [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2614 ) ) ) [metadata] => Array ( ) [display] => 1 [description] => ) ) [#formatter] => file_default [0] => Array ( [#theme] => file_link [#file] => stdClass Object ( [fid] => 128185 [uid] => 4 [filename] => 24 Selezione 2024N6 valutazione titoli web.pdf [uri] => public://2024/24 Selezione 2024N6 valutazione titoli web.pdf [filemime] => application/pdf [filesize] => 182795 [status] => 1 [timestamp] => 1710152464 [type] => document [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2614 ) ) ) [metadata] => Array ( ) [display] => 1 [description] => ) ) ) [links] => Array ( [#theme] => links__node [#pre_render] => Array ( [0] => drupal_pre_render_links ) [#attributes] => Array ( [class] => Array ( [0] => links [1] => inline ) ) [node] => Array ( [#theme] => links__node__node [#links] => Array ( [node-readmore] => Array ( [title] => Read more about 2024N46 Esito valutazione titoli [href] => node/108442 [html] => 1 [attributes] => Array ( [rel] => tag [title] => 2024N46 Esito valutazione titoli ) ) ) [#attributes] => Array ( [class] => Array ( [0] => links [1] => inline ) ) ) ) )

Verbale sorteggio del 8 marzo 2024

Array ( [field_titolo_frontend_all] => Array ( [#theme] => field [#weight] => -4 [#title] => Titolo frontend [#access] => 1 [#label_display] => above [#view_mode] => teaser [#language] => und [#field_name] => field_titolo_frontend_all [#field_type] => text_long [#field_translatable] => 0 [#entity_type] => node [#bundle] => allegato [#object] => stdClass Object ( [vid] => 451950 [uid] => 4 [title] => Verbale sorteggio del 8 marzo 2024 [log] => [status] => 1 [comment] => 0 [promote] => 1 [sticky] => 0 [nid] => 108441 [type] => allegato [language] => it [created] => 1710151930 [changed] => 1711531347 [tnid] => 0 [translate] => 0 [revision_timestamp] => 1711531347 [revision_uid] => 32 [taxonomy_vocabulary_2] => Array ( ) [taxonomy_vocabulary_8] => Array ( ) [body] => Array ( ) [field_titolo_frontend_all] => Array ( [und] => Array ( [0] => Array ( [value] => Verbale sorteggio dell'8 marzo 2024 [format] => [safe_value] => Verbale sorteggio dell'8 marzo 2024 ) ) ) [field_allegato_file] => Array ( [und] => Array ( [0] => Array ( [fid] => 128182 [uid] => 4 [filename] => Verbale sorteggio telematico 8.3.2024.pdf [uri] => public://2024/Verbale sorteggio telematico 8.3.2024.pdf [filemime] => application/pdf [filesize] => 186994 [status] => 1 [timestamp] => 1710151926 [type] => document [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2614 ) ) ) [metadata] => Array ( ) [display] => 1 [description] => ) [1] => Array ( [fid] => 128183 [uid] => 4 [filename] => Dichiarazione concordanza - Prof. Bonetto.pdf [uri] => public://2024/Dichiarazione concordanza - Prof. Bonetto_1.pdf [filemime] => application/pdf [filesize] => 239849 [status] => 1 [timestamp] => 1710151962 [type] => document [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2614 ) ) ) [metadata] => Array ( ) [display] => 1 [description] => ) [2] => Array ( [fid] => 128184 [uid] => 4 [filename] => Dichiarazione concordanza - Prof. Perilongo.pdf [uri] => public://2024/Dichiarazione concordanza - Prof. Perilongo_1.pdf [filemime] => application/pdf [filesize] => 178511 [status] => 1 [timestamp] => 1710151985 [type] => document [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2614 ) ) ) [metadata] => Array ( ) [display] => 1 [description] => ) ) ) [name] => simonetta.capparotto [picture] => 0 [data] => a:2:{s:13:"form_build_id";s:37:"form-fe5ebd9e5e240c4294455b6b42fa6a76";s:14:"wysiwyg_status";a:1:{i:1;i:1;}} [num_revisions] => 1 [current_revision_id] => 451950 [is_current] => 1 [is_pending] => [revision_moderation] => [entity_view_prepared] => 1 ) [#items] => Array ( [0] => Array ( [value] => Verbale sorteggio dell'8 marzo 2024 [format] => [safe_value] => Verbale sorteggio dell'8 marzo 2024 ) ) [#formatter] => text_default [0] => Array ( [#markup] => Verbale sorteggio dell'8 marzo 2024 ) ) [field_allegato_file] => Array ( [#theme] => field [#weight] => -3 [#title] => File [#access] => 1 [#label_display] => above [#view_mode] => teaser [#language] => und [#field_name] => field_allegato_file [#field_type] => file [#field_translatable] => 0 [#entity_type] => node [#bundle] => allegato [#object] => stdClass Object ( [vid] => 451950 [uid] => 4 [title] => Verbale sorteggio del 8 marzo 2024 [log] => [status] => 1 [comment] => 0 [promote] => 1 [sticky] => 0 [nid] => 108441 [type] => allegato [language] => it [created] => 1710151930 [changed] => 1711531347 [tnid] => 0 [translate] => 0 [revision_timestamp] => 1711531347 [revision_uid] => 32 [taxonomy_vocabulary_2] => Array ( ) [taxonomy_vocabulary_8] => Array ( ) [body] => Array ( ) [field_titolo_frontend_all] => Array ( [und] => Array ( [0] => Array ( [value] => Verbale sorteggio dell'8 marzo 2024 [format] => [safe_value] => Verbale sorteggio dell'8 marzo 2024 ) ) ) [field_allegato_file] => Array ( [und] => Array ( [0] => Array ( [fid] => 128182 [uid] => 4 [filename] => Verbale sorteggio telematico 8.3.2024.pdf [uri] => public://2024/Verbale sorteggio telematico 8.3.2024.pdf [filemime] => application/pdf [filesize] => 186994 [status] => 1 [timestamp] => 1710151926 [type] => document [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2614 ) ) ) [metadata] => Array ( ) [display] => 1 [description] => ) [1] => Array ( [fid] => 128183 [uid] => 4 [filename] => Dichiarazione concordanza - Prof. Bonetto.pdf [uri] => public://2024/Dichiarazione concordanza - Prof. Bonetto_1.pdf [filemime] => application/pdf [filesize] => 239849 [status] => 1 [timestamp] => 1710151962 [type] => document [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2614 ) ) ) [metadata] => Array ( ) [display] => 1 [description] => ) [2] => Array ( [fid] => 128184 [uid] => 4 [filename] => Dichiarazione concordanza - Prof. Perilongo.pdf [uri] => public://2024/Dichiarazione concordanza - Prof. Perilongo_1.pdf [filemime] => application/pdf [filesize] => 178511 [status] => 1 [timestamp] => 1710151985 [type] => document [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2614 ) ) ) [metadata] => Array ( ) [display] => 1 [description] => ) ) ) [name] => simonetta.capparotto [picture] => 0 [data] => a:2:{s:13:"form_build_id";s:37:"form-fe5ebd9e5e240c4294455b6b42fa6a76";s:14:"wysiwyg_status";a:1:{i:1;i:1;}} [num_revisions] => 1 [current_revision_id] => 451950 [is_current] => 1 [is_pending] => [revision_moderation] => [entity_view_prepared] => 1 ) [#items] => Array ( [0] => Array ( [fid] => 128182 [uid] => 4 [filename] => Verbale sorteggio telematico 8.3.2024.pdf [uri] => public://2024/Verbale sorteggio telematico 8.3.2024.pdf [filemime] => application/pdf [filesize] => 186994 [status] => 1 [timestamp] => 1710151926 [type] => document [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2614 ) ) ) [metadata] => Array ( ) [display] => 1 [description] => ) [1] => Array ( [fid] => 128183 [uid] => 4 [filename] => Dichiarazione concordanza - Prof. Bonetto.pdf [uri] => public://2024/Dichiarazione concordanza - Prof. Bonetto_1.pdf [filemime] => application/pdf [filesize] => 239849 [status] => 1 [timestamp] => 1710151962 [type] => document [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2614 ) ) ) [metadata] => Array ( ) [display] => 1 [description] => ) [2] => Array ( [fid] => 128184 [uid] => 4 [filename] => Dichiarazione concordanza - Prof. Perilongo.pdf [uri] => public://2024/Dichiarazione concordanza - Prof. Perilongo_1.pdf [filemime] => application/pdf [filesize] => 178511 [status] => 1 [timestamp] => 1710151985 [type] => document [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2614 ) ) ) [metadata] => Array ( ) [display] => 1 [description] => ) ) [#formatter] => file_default [0] => Array ( [#theme] => file_link [#file] => stdClass Object ( [fid] => 128182 [uid] => 4 [filename] => Verbale sorteggio telematico 8.3.2024.pdf [uri] => public://2024/Verbale sorteggio telematico 8.3.2024.pdf [filemime] => application/pdf [filesize] => 186994 [status] => 1 [timestamp] => 1710151926 [type] => document [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2614 ) ) ) [metadata] => Array ( ) [display] => 1 [description] => ) ) [1] => Array ( [#theme] => file_link [#file] => stdClass Object ( [fid] => 128183 [uid] => 4 [filename] => Dichiarazione concordanza - Prof. Bonetto.pdf [uri] => public://2024/Dichiarazione concordanza - Prof. Bonetto_1.pdf [filemime] => application/pdf [filesize] => 239849 [status] => 1 [timestamp] => 1710151962 [type] => document [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2614 ) ) ) [metadata] => Array ( ) [display] => 1 [description] => ) ) [2] => Array ( [#theme] => file_link [#file] => stdClass Object ( [fid] => 128184 [uid] => 4 [filename] => Dichiarazione concordanza - Prof. Perilongo.pdf [uri] => public://2024/Dichiarazione concordanza - Prof. Perilongo_1.pdf [filemime] => application/pdf [filesize] => 178511 [status] => 1 [timestamp] => 1710151985 [type] => document [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2614 ) ) ) [metadata] => Array ( ) [display] => 1 [description] => ) ) ) [links] => Array ( [#theme] => links__node [#pre_render] => Array ( [0] => drupal_pre_render_links ) [#attributes] => Array ( [class] => Array ( [0] => links [1] => inline ) ) [node] => Array ( [#theme] => links__node__node [#links] => Array ( [node-readmore] => Array ( [title] => Read more about Verbale sorteggio del 8 marzo 2024 [href] => node/108441 [html] => 1 [attributes] => Array ( [rel] => tag [title] => Verbale sorteggio del 8 marzo 2024 ) ) ) [#attributes] => Array ( [class] => Array ( [0] => links [1] => inline ) ) ) ) )

2023RUA07 Allegato 2 - Verbale 2 bis - elenco candidati e convocazion

Array ( [field_titolo_frontend_all] => Array ( [#theme] => field [#weight] => -4 [#title] => Titolo frontend [#access] => 1 [#label_display] => above [#view_mode] => teaser [#language] => und [#field_name] => field_titolo_frontend_all [#field_type] => text_long [#field_translatable] => 0 [#entity_type] => node [#bundle] => allegato [#object] => stdClass Object ( [vid] => 451932 [uid] => 8831 [title] => 2023RUA07 Allegato 2 - Verbale 2 bis - elenco candidati e convocazion [log] => [status] => 1 [comment] => 0 [promote] => 1 [sticky] => 0 [nid] => 108440 [type] => allegato [language] => it [created] => 1710150429 [changed] => 1710150444 [tnid] => 0 [translate] => 0 [revision_timestamp] => 1710150444 [revision_uid] => 2032 [taxonomy_vocabulary_2] => Array ( ) [taxonomy_vocabulary_8] => Array ( ) [body] => Array ( ) [field_titolo_frontend_all] => Array ( [und] => Array ( [0] => Array ( [value] => Verbale 2 bis - elenco candidati e convocazione [format] => [safe_value] => Verbale 2 bis - elenco candidati e convocazione ) ) ) [field_allegato_file] => Array ( [und] => Array ( [0] => Array ( [fid] => 128181 [uid] => 2032 [filename] => VERB 2bis RTDA_signed-signed.pdf [uri] => public://2024/VERB 2bis RTDA_signed-signed.pdf [filemime] => application/pdf [filesize] => 353263 [status] => 1 [timestamp] => 1710150414 [type] => document [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2614 ) ) ) [metadata] => Array ( ) [display] => 1 [description] => ) ) ) [name] => carriere.docenti [picture] => 0 [data] => [num_revisions] => 1 [current_revision_id] => 451932 [is_current] => 1 [is_pending] => [revision_moderation] => [entity_view_prepared] => 1 ) [#items] => Array ( [0] => Array ( [value] => Verbale 2 bis - elenco candidati e convocazione [format] => [safe_value] => Verbale 2 bis - elenco candidati e convocazione ) ) [#formatter] => text_default [0] => Array ( [#markup] => Verbale 2 bis - elenco candidati e convocazione ) ) [field_allegato_file] => Array ( [#theme] => field [#weight] => -3 [#title] => File [#access] => 1 [#label_display] => above [#view_mode] => teaser [#language] => und [#field_name] => field_allegato_file [#field_type] => file [#field_translatable] => 0 [#entity_type] => node [#bundle] => allegato [#object] => stdClass Object ( [vid] => 451932 [uid] => 8831 [title] => 2023RUA07 Allegato 2 - Verbale 2 bis - elenco candidati e convocazion [log] => [status] => 1 [comment] => 0 [promote] => 1 [sticky] => 0 [nid] => 108440 [type] => allegato [language] => it [created] => 1710150429 [changed] => 1710150444 [tnid] => 0 [translate] => 0 [revision_timestamp] => 1710150444 [revision_uid] => 2032 [taxonomy_vocabulary_2] => Array ( ) [taxonomy_vocabulary_8] => Array ( ) [body] => Array ( ) [field_titolo_frontend_all] => Array ( [und] => Array ( [0] => Array ( [value] => Verbale 2 bis - elenco candidati e convocazione [format] => [safe_value] => Verbale 2 bis - elenco candidati e convocazione ) ) ) [field_allegato_file] => Array ( [und] => Array ( [0] => Array ( [fid] => 128181 [uid] => 2032 [filename] => VERB 2bis RTDA_signed-signed.pdf [uri] => public://2024/VERB 2bis RTDA_signed-signed.pdf [filemime] => application/pdf [filesize] => 353263 [status] => 1 [timestamp] => 1710150414 [type] => document [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2614 ) ) ) [metadata] => Array ( ) [display] => 1 [description] => ) ) ) [name] => carriere.docenti [picture] => 0 [data] => [num_revisions] => 1 [current_revision_id] => 451932 [is_current] => 1 [is_pending] => [revision_moderation] => [entity_view_prepared] => 1 ) [#items] => Array ( [0] => Array ( [fid] => 128181 [uid] => 2032 [filename] => VERB 2bis RTDA_signed-signed.pdf [uri] => public://2024/VERB 2bis RTDA_signed-signed.pdf [filemime] => application/pdf [filesize] => 353263 [status] => 1 [timestamp] => 1710150414 [type] => document [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2614 ) ) ) [metadata] => Array ( ) [display] => 1 [description] => ) ) [#formatter] => file_default [0] => Array ( [#theme] => file_link [#file] => stdClass Object ( [fid] => 128181 [uid] => 2032 [filename] => VERB 2bis RTDA_signed-signed.pdf [uri] => public://2024/VERB 2bis RTDA_signed-signed.pdf [filemime] => application/pdf [filesize] => 353263 [status] => 1 [timestamp] => 1710150414 [type] => document [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2614 ) ) ) [metadata] => Array ( ) [display] => 1 [description] => ) ) ) [links] => Array ( [#theme] => links__node [#pre_render] => Array ( [0] => drupal_pre_render_links ) [#attributes] => Array ( [class] => Array ( [0] => links [1] => inline ) ) [node] => Array ( [#theme] => links__node__node [#links] => Array ( [node-readmore] => Array ( [title] => Read more about 2023RUA07 Allegato 2 - Verbale 2 bis - elenco candidati e convocazion [href] => node/108440 [html] => 1 [attributes] => Array ( [rel] => tag [title] => 2023RUA07 Allegato 2 - Verbale 2 bis - elenco candidati e convocazion ) ) ) [#attributes] => Array ( [class] => Array ( [0] => links [1] => inline ) ) ) ) )

2024PA510 - Verbale 1 - Criteri

Array ( [field_titolo_frontend_all] => Array ( [#theme] => field [#weight] => -4 [#title] => Titolo frontend [#access] => 1 [#label_display] => above [#view_mode] => teaser [#language] => und [#field_name] => field_titolo_frontend_all [#field_type] => text_long [#field_translatable] => 0 [#entity_type] => node [#bundle] => allegato [#object] => stdClass Object ( [vid] => 451924 [uid] => 8831 [title] => 2024PA510 - Verbale 1 - Criteri [log] => [status] => 1 [comment] => 0 [promote] => 1 [sticky] => 0 [nid] => 108439 [type] => allegato [language] => it [created] => 1710148488 [changed] => 1710847474 [tnid] => 0 [translate] => 0 [revision_timestamp] => 1710847474 [revision_uid] => 102 [taxonomy_vocabulary_2] => Array ( ) [taxonomy_vocabulary_8] => Array ( ) [body] => Array ( ) [field_titolo_frontend_all] => Array ( [und] => Array ( [0] => Array ( [value] => Verbale 1 - Criteri [format] => [safe_value] => Verbale 1 - Criteri ) ) ) [field_allegato_file] => Array ( [und] => Array ( [0] => Array ( [fid] => 128180 [uid] => 2032 [filename] => Verbale 1 - 2024PA510.pdf [uri] => public://2024/Verbale 1 - 2024PA510.pdf [filemime] => application/pdf [filesize] => 312283 [status] => 1 [timestamp] => 1710148483 [type] => document [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2614 ) ) ) [metadata] => Array ( ) [display] => 1 [description] => ) ) ) [name] => carriere.docenti [picture] => 0 [data] => [num_revisions] => 1 [current_revision_id] => 451924 [is_current] => 1 [is_pending] => [revision_moderation] => [entity_view_prepared] => 1 ) [#items] => Array ( [0] => Array ( [value] => Verbale 1 - Criteri [format] => [safe_value] => Verbale 1 - Criteri ) ) [#formatter] => text_default [0] => Array ( [#markup] => Verbale 1 - Criteri ) ) [field_allegato_file] => Array ( [#theme] => field [#weight] => -3 [#title] => File [#access] => 1 [#label_display] => above [#view_mode] => teaser [#language] => und [#field_name] => field_allegato_file [#field_type] => file [#field_translatable] => 0 [#entity_type] => node [#bundle] => allegato [#object] => stdClass Object ( [vid] => 451924 [uid] => 8831 [title] => 2024PA510 - Verbale 1 - Criteri [log] => [status] => 1 [comment] => 0 [promote] => 1 [sticky] => 0 [nid] => 108439 [type] => allegato [language] => it [created] => 1710148488 [changed] => 1710847474 [tnid] => 0 [translate] => 0 [revision_timestamp] => 1710847474 [revision_uid] => 102 [taxonomy_vocabulary_2] => Array ( ) [taxonomy_vocabulary_8] => Array ( ) [body] => Array ( ) [field_titolo_frontend_all] => Array ( [und] => Array ( [0] => Array ( [value] => Verbale 1 - Criteri [format] => [safe_value] => Verbale 1 - Criteri ) ) ) [field_allegato_file] => Array ( [und] => Array ( [0] => Array ( [fid] => 128180 [uid] => 2032 [filename] => Verbale 1 - 2024PA510.pdf [uri] => public://2024/Verbale 1 - 2024PA510.pdf [filemime] => application/pdf [filesize] => 312283 [status] => 1 [timestamp] => 1710148483 [type] => document [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2614 ) ) ) [metadata] => Array ( ) [display] => 1 [description] => ) ) ) [name] => carriere.docenti [picture] => 0 [data] => [num_revisions] => 1 [current_revision_id] => 451924 [is_current] => 1 [is_pending] => [revision_moderation] => [entity_view_prepared] => 1 ) [#items] => Array ( [0] => Array ( [fid] => 128180 [uid] => 2032 [filename] => Verbale 1 - 2024PA510.pdf [uri] => public://2024/Verbale 1 - 2024PA510.pdf [filemime] => application/pdf [filesize] => 312283 [status] => 1 [timestamp] => 1710148483 [type] => document [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2614 ) ) ) [metadata] => Array ( ) [display] => 1 [description] => ) ) [#formatter] => file_default [0] => Array ( [#theme] => file_link [#file] => stdClass Object ( [fid] => 128180 [uid] => 2032 [filename] => Verbale 1 - 2024PA510.pdf [uri] => public://2024/Verbale 1 - 2024PA510.pdf [filemime] => application/pdf [filesize] => 312283 [status] => 1 [timestamp] => 1710148483 [type] => document [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2614 ) ) ) [metadata] => Array ( ) [display] => 1 [description] => ) ) ) [links] => Array ( [#theme] => links__node [#pre_render] => Array ( [0] => drupal_pre_render_links ) [#attributes] => Array ( [class] => Array ( [0] => links [1] => inline ) ) [node] => Array ( [#theme] => links__node__node [#links] => Array ( [node-readmore] => Array ( [title] => Read more about 2024PA510 - Verbale 1 - Criteri [href] => node/108439 [html] => 1 [attributes] => Array ( [rel] => tag [title] => 2024PA510 - Verbale 1 - Criteri ) ) ) [#attributes] => Array ( [class] => Array ( [0] => links [1] => inline ) ) ) ) )

2023S65 Quesiti colloquio

Array ( [field_titolo_frontend_all] => Array ( [#theme] => field [#weight] => -4 [#title] => Titolo frontend [#access] => 1 [#label_display] => above [#view_mode] => teaser [#language] => und [#field_name] => field_titolo_frontend_all [#field_type] => text_long [#field_translatable] => 0 [#entity_type] => node [#bundle] => allegato [#object] => stdClass Object ( [vid] => 451917 [uid] => 4 [title] => 2023S65 Quesiti colloquio [log] => [status] => 1 [comment] => 0 [promote] => 1 [sticky] => 0 [nid] => 108438 [type] => allegato [language] => it [created] => 1710147705 [changed] => 1710147705 [tnid] => 0 [translate] => 0 [revision_timestamp] => 1710147705 [revision_uid] => 4 [taxonomy_vocabulary_2] => Array ( ) [taxonomy_vocabulary_8] => Array ( ) [body] => Array ( ) [field_titolo_frontend_all] => Array ( [und] => Array ( [0] => Array ( [value] => Quesiti colloquio [format] => [safe_value] => Quesiti colloquio ) ) ) [field_allegato_file] => Array ( [und] => Array ( [0] => Array ( [fid] => 128179 [uid] => 4 [filename] => 28 quesiti colloquio.pdf [uri] => public://2024/28 quesiti colloquio.pdf [filemime] => application/pdf [filesize] => 262654 [status] => 1 [timestamp] => 1710147699 [type] => document [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2614 ) ) ) [metadata] => Array ( ) [display] => 1 [description] => ) ) ) [name] => simonetta.capparotto [picture] => 0 [data] => a:2:{s:13:"form_build_id";s:37:"form-fe5ebd9e5e240c4294455b6b42fa6a76";s:14:"wysiwyg_status";a:1:{i:1;i:1;}} [num_revisions] => 1 [current_revision_id] => 451917 [is_current] => 1 [is_pending] => [revision_moderation] => [entity_view_prepared] => 1 ) [#items] => Array ( [0] => Array ( [value] => Quesiti colloquio [format] => [safe_value] => Quesiti colloquio ) ) [#formatter] => text_default [0] => Array ( [#markup] => Quesiti colloquio ) ) [field_allegato_file] => Array ( [#theme] => field [#weight] => -3 [#title] => File [#access] => 1 [#label_display] => above [#view_mode] => teaser [#language] => und [#field_name] => field_allegato_file [#field_type] => file [#field_translatable] => 0 [#entity_type] => node [#bundle] => allegato [#object] => stdClass Object ( [vid] => 451917 [uid] => 4 [title] => 2023S65 Quesiti colloquio [log] => [status] => 1 [comment] => 0 [promote] => 1 [sticky] => 0 [nid] => 108438 [type] => allegato [language] => it [created] => 1710147705 [changed] => 1710147705 [tnid] => 0 [translate] => 0 [revision_timestamp] => 1710147705 [revision_uid] => 4 [taxonomy_vocabulary_2] => Array ( ) [taxonomy_vocabulary_8] => Array ( ) [body] => Array ( ) [field_titolo_frontend_all] => Array ( [und] => Array ( [0] => Array ( [value] => Quesiti colloquio [format] => [safe_value] => Quesiti colloquio ) ) ) [field_allegato_file] => Array ( [und] => Array ( [0] => Array ( [fid] => 128179 [uid] => 4 [filename] => 28 quesiti colloquio.pdf [uri] => public://2024/28 quesiti colloquio.pdf [filemime] => application/pdf [filesize] => 262654 [status] => 1 [timestamp] => 1710147699 [type] => document [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2614 ) ) ) [metadata] => Array ( ) [display] => 1 [description] => ) ) ) [name] => simonetta.capparotto [picture] => 0 [data] => a:2:{s:13:"form_build_id";s:37:"form-fe5ebd9e5e240c4294455b6b42fa6a76";s:14:"wysiwyg_status";a:1:{i:1;i:1;}} [num_revisions] => 1 [current_revision_id] => 451917 [is_current] => 1 [is_pending] => [revision_moderation] => [entity_view_prepared] => 1 ) [#items] => Array ( [0] => Array ( [fid] => 128179 [uid] => 4 [filename] => 28 quesiti colloquio.pdf [uri] => public://2024/28 quesiti colloquio.pdf [filemime] => application/pdf [filesize] => 262654 [status] => 1 [timestamp] => 1710147699 [type] => document [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2614 ) ) ) [metadata] => Array ( ) [display] => 1 [description] => ) ) [#formatter] => file_default [0] => Array ( [#theme] => file_link [#file] => stdClass Object ( [fid] => 128179 [uid] => 4 [filename] => 28 quesiti colloquio.pdf [uri] => public://2024/28 quesiti colloquio.pdf [filemime] => application/pdf [filesize] => 262654 [status] => 1 [timestamp] => 1710147699 [type] => document [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2614 ) ) ) [metadata] => Array ( ) [display] => 1 [description] => ) ) ) [links] => Array ( [#theme] => links__node [#pre_render] => Array ( [0] => drupal_pre_render_links ) [#attributes] => Array ( [class] => Array ( [0] => links [1] => inline ) ) [node] => Array ( [#theme] => links__node__node [#links] => Array ( [node-readmore] => Array ( [title] => Read more about 2023S65 Quesiti colloquio [href] => node/108438 [html] => 1 [attributes] => Array ( [rel] => tag [title] => 2023S65 Quesiti colloquio ) ) ) [#attributes] => Array ( [class] => Array ( [0] => links [1] => inline ) ) ) ) )

2023S65 Quesiti prova scritta

Array ( [field_titolo_frontend_all] => Array ( [#theme] => field [#weight] => -4 [#title] => Titolo frontend [#access] => 1 [#label_display] => above [#view_mode] => teaser [#language] => und [#field_name] => field_titolo_frontend_all [#field_type] => text_long [#field_translatable] => 0 [#entity_type] => node [#bundle] => allegato [#object] => stdClass Object ( [vid] => 451916 [uid] => 4 [title] => 2023S65 Quesiti prova scritta [log] => [status] => 1 [comment] => 0 [promote] => 1 [sticky] => 0 [nid] => 108437 [type] => allegato [language] => it [created] => 1710147663 [changed] => 1710147663 [tnid] => 0 [translate] => 0 [revision_timestamp] => 1710147663 [revision_uid] => 4 [taxonomy_vocabulary_2] => Array ( ) [taxonomy_vocabulary_8] => Array ( ) [body] => Array ( ) [field_titolo_frontend_all] => Array ( [und] => Array ( [0] => Array ( [value] => Quesiti prova scritta [format] => [safe_value] => Quesiti prova scritta ) ) ) [field_allegato_file] => Array ( [und] => Array ( [0] => Array ( [fid] => 128178 [uid] => 4 [filename] => 27 quesiti prova scritta.pdf [uri] => public://2024/27 quesiti prova scritta.pdf [filemime] => application/pdf [filesize] => 319501 [status] => 1 [timestamp] => 1710147658 [type] => document [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2614 ) ) ) [metadata] => Array ( ) [display] => 1 [description] => ) ) ) [name] => simonetta.capparotto [picture] => 0 [data] => a:2:{s:13:"form_build_id";s:37:"form-fe5ebd9e5e240c4294455b6b42fa6a76";s:14:"wysiwyg_status";a:1:{i:1;i:1;}} [num_revisions] => 1 [current_revision_id] => 451916 [is_current] => 1 [is_pending] => [revision_moderation] => [entity_view_prepared] => 1 ) [#items] => Array ( [0] => Array ( [value] => Quesiti prova scritta [format] => [safe_value] => Quesiti prova scritta ) ) [#formatter] => text_default [0] => Array ( [#markup] => Quesiti prova scritta ) ) [field_allegato_file] => Array ( [#theme] => field [#weight] => -3 [#title] => File [#access] => 1 [#label_display] => above [#view_mode] => teaser [#language] => und [#field_name] => field_allegato_file [#field_type] => file [#field_translatable] => 0 [#entity_type] => node [#bundle] => allegato [#object] => stdClass Object ( [vid] => 451916 [uid] => 4 [title] => 2023S65 Quesiti prova scritta [log] => [status] => 1 [comment] => 0 [promote] => 1 [sticky] => 0 [nid] => 108437 [type] => allegato [language] => it [created] => 1710147663 [changed] => 1710147663 [tnid] => 0 [translate] => 0 [revision_timestamp] => 1710147663 [revision_uid] => 4 [taxonomy_vocabulary_2] => Array ( ) [taxonomy_vocabulary_8] => Array ( ) [body] => Array ( ) [field_titolo_frontend_all] => Array ( [und] => Array ( [0] => Array ( [value] => Quesiti prova scritta [format] => [safe_value] => Quesiti prova scritta ) ) ) [field_allegato_file] => Array ( [und] => Array ( [0] => Array ( [fid] => 128178 [uid] => 4 [filename] => 27 quesiti prova scritta.pdf [uri] => public://2024/27 quesiti prova scritta.pdf [filemime] => application/pdf [filesize] => 319501 [status] => 1 [timestamp] => 1710147658 [type] => document [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2614 ) ) ) [metadata] => Array ( ) [display] => 1 [description] => ) ) ) [name] => simonetta.capparotto [picture] => 0 [data] => a:2:{s:13:"form_build_id";s:37:"form-fe5ebd9e5e240c4294455b6b42fa6a76";s:14:"wysiwyg_status";a:1:{i:1;i:1;}} [num_revisions] => 1 [current_revision_id] => 451916 [is_current] => 1 [is_pending] => [revision_moderation] => [entity_view_prepared] => 1 ) [#items] => Array ( [0] => Array ( [fid] => 128178 [uid] => 4 [filename] => 27 quesiti prova scritta.pdf [uri] => public://2024/27 quesiti prova scritta.pdf [filemime] => application/pdf [filesize] => 319501 [status] => 1 [timestamp] => 1710147658 [type] => document [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2614 ) ) ) [metadata] => Array ( ) [display] => 1 [description] => ) ) [#formatter] => file_default [0] => Array ( [#theme] => file_link [#file] => stdClass Object ( [fid] => 128178 [uid] => 4 [filename] => 27 quesiti prova scritta.pdf [uri] => public://2024/27 quesiti prova scritta.pdf [filemime] => application/pdf [filesize] => 319501 [status] => 1 [timestamp] => 1710147658 [type] => document [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2614 ) ) ) [metadata] => Array ( ) [display] => 1 [description] => ) ) ) [links] => Array ( [#theme] => links__node [#pre_render] => Array ( [0] => drupal_pre_render_links ) [#attributes] => Array ( [class] => Array ( [0] => links [1] => inline ) ) [node] => Array ( [#theme] => links__node__node [#links] => Array ( [node-readmore] => Array ( [title] => Read more about 2023S65 Quesiti prova scritta [href] => node/108437 [html] => 1 [attributes] => Array ( [rel] => tag [title] => 2023S65 Quesiti prova scritta ) ) ) [#attributes] => Array ( [class] => Array ( [0] => links [1] => inline ) ) ) ) )

2023S65 Criteri di valutazione prove d'esame

Array ( [field_titolo_frontend_all] => Array ( [#theme] => field [#weight] => -4 [#title] => Titolo frontend [#access] => 1 [#label_display] => above [#view_mode] => teaser [#language] => und [#field_name] => field_titolo_frontend_all [#field_type] => text_long [#field_translatable] => 0 [#entity_type] => node [#bundle] => allegato [#object] => stdClass Object ( [vid] => 451915 [uid] => 4 [title] => 2023S65 Criteri di valutazione prove d'esame [log] => [status] => 1 [comment] => 0 [promote] => 1 [sticky] => 0 [nid] => 108436 [type] => allegato [language] => it [created] => 1710147617 [changed] => 1710147617 [tnid] => 0 [translate] => 0 [revision_timestamp] => 1710147617 [revision_uid] => 4 [taxonomy_vocabulary_2] => Array ( ) [taxonomy_vocabulary_8] => Array ( ) [body] => Array ( ) [field_titolo_frontend_all] => Array ( [und] => Array ( [0] => Array ( [value] => Criteri di valutazione prove d'esame [format] => [safe_value] => Criteri di valutazione prove d'esame ) ) ) [field_allegato_file] => Array ( [und] => Array ( [0] => Array ( [fid] => 128177 [uid] => 4 [filename] => 26 criteri di valutazione.pdf [uri] => public://2024/26 criteri di valutazione.pdf [filemime] => application/pdf [filesize] => 332606 [status] => 1 [timestamp] => 1710147612 [type] => document [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2614 ) ) ) [metadata] => Array ( ) [display] => 1 [description] => ) ) ) [name] => simonetta.capparotto [picture] => 0 [data] => a:2:{s:13:"form_build_id";s:37:"form-fe5ebd9e5e240c4294455b6b42fa6a76";s:14:"wysiwyg_status";a:1:{i:1;i:1;}} [num_revisions] => 1 [current_revision_id] => 451915 [is_current] => 1 [is_pending] => [revision_moderation] => [entity_view_prepared] => 1 ) [#items] => Array ( [0] => Array ( [value] => Criteri di valutazione prove d'esame [format] => [safe_value] => Criteri di valutazione prove d'esame ) ) [#formatter] => text_default [0] => Array ( [#markup] => Criteri di valutazione prove d'esame ) ) [field_allegato_file] => Array ( [#theme] => field [#weight] => -3 [#title] => File [#access] => 1 [#label_display] => above [#view_mode] => teaser [#language] => und [#field_name] => field_allegato_file [#field_type] => file [#field_translatable] => 0 [#entity_type] => node [#bundle] => allegato [#object] => stdClass Object ( [vid] => 451915 [uid] => 4 [title] => 2023S65 Criteri di valutazione prove d'esame [log] => [status] => 1 [comment] => 0 [promote] => 1 [sticky] => 0 [nid] => 108436 [type] => allegato [language] => it [created] => 1710147617 [changed] => 1710147617 [tnid] => 0 [translate] => 0 [revision_timestamp] => 1710147617 [revision_uid] => 4 [taxonomy_vocabulary_2] => Array ( ) [taxonomy_vocabulary_8] => Array ( ) [body] => Array ( ) [field_titolo_frontend_all] => Array ( [und] => Array ( [0] => Array ( [value] => Criteri di valutazione prove d'esame [format] => [safe_value] => Criteri di valutazione prove d'esame ) ) ) [field_allegato_file] => Array ( [und] => Array ( [0] => Array ( [fid] => 128177 [uid] => 4 [filename] => 26 criteri di valutazione.pdf [uri] => public://2024/26 criteri di valutazione.pdf [filemime] => application/pdf [filesize] => 332606 [status] => 1 [timestamp] => 1710147612 [type] => document [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2614 ) ) ) [metadata] => Array ( ) [display] => 1 [description] => ) ) ) [name] => simonetta.capparotto [picture] => 0 [data] => a:2:{s:13:"form_build_id";s:37:"form-fe5ebd9e5e240c4294455b6b42fa6a76";s:14:"wysiwyg_status";a:1:{i:1;i:1;}} [num_revisions] => 1 [current_revision_id] => 451915 [is_current] => 1 [is_pending] => [revision_moderation] => [entity_view_prepared] => 1 ) [#items] => Array ( [0] => Array ( [fid] => 128177 [uid] => 4 [filename] => 26 criteri di valutazione.pdf [uri] => public://2024/26 criteri di valutazione.pdf [filemime] => application/pdf [filesize] => 332606 [status] => 1 [timestamp] => 1710147612 [type] => document [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2614 ) ) ) [metadata] => Array ( ) [display] => 1 [description] => ) ) [#formatter] => file_default [0] => Array ( [#theme] => file_link [#file] => stdClass Object ( [fid] => 128177 [uid] => 4 [filename] => 26 criteri di valutazione.pdf [uri] => public://2024/26 criteri di valutazione.pdf [filemime] => application/pdf [filesize] => 332606 [status] => 1 [timestamp] => 1710147612 [type] => document [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2614 ) ) ) [metadata] => Array ( ) [display] => 1 [description] => ) ) ) [links] => Array ( [#theme] => links__node [#pre_render] => Array ( [0] => drupal_pre_render_links ) [#attributes] => Array ( [class] => Array ( [0] => links [1] => inline ) ) [node] => Array ( [#theme] => links__node__node [#links] => Array ( [node-readmore] => Array ( [title] => Read more about 2023S65 Criteri di valutazione prove d'esame [href] => node/108436 [html] => 1 [attributes] => Array ( [rel] => tag [title] => 2023S65 Criteri di valutazione prove d'esame ) ) ) [#attributes] => Array ( [class] => Array ( [0] => links [1] => inline ) ) ) ) )

An Innovative Approach to Treating Prostate Cancer

Array ( [field_link_esterno_news] => Array ( [#theme] => field [#weight] => -1 [#title] => Link esterno news [#access] => 1 [#label_display] => above [#view_mode] => teaser [#language] => und [#field_name] => field_link_esterno_news [#field_type] => text_long [#field_translatable] => 0 [#entity_type] => node [#bundle] => box_lancio_news [#object] => stdClass Object ( [vid] => 451914 [uid] => 2032 [title] => An Innovative Approach to Treating Prostate Cancer [log] => [status] => 1 [comment] => 0 [promote] => 1 [sticky] => 0 [nid] => 108435 [type] => box_lancio_news [language] => it [created] => 1710147247 [changed] => 1710147247 [tnid] => 0 [translate] => 0 [revision_timestamp] => 1710147247 [revision_uid] => 2032 [body] => Array ( [und] => Array ( [0] => Array ( [value] =>

Prostate cancer is the second leading cause of cancer-related mortality among men worldwide. Although much research concentrates on this form of cancer, the mechanisms underlying resistance to therapy remain poorly understood. Cellular senescence can exert dual effects in tumors, either suppressing or promoting tumor progression. Consequently, the clinical challenge lies in developing therapies that safely enhance senescence in cancer, favoring tumor-suppressive factors.

The study Retinoic acid receptor activation reprograms senescence response and enhances anti-tumor activity of natural killer cells, published by researchers at the Veneto Institute of Molecular Medicine (VIMM), the University of Padua, and the Oncology Research Institute (IOR) of Bellinzona, offer an innovative approach to treating prostate cancer. The promising breakthrough involves cellular senescence and a subset of anti-tumor immune system cells known as natural killer cells (NK cells).

Cellular senescence can halt the proliferation of tumor cells but under specific circumstances, it can also promote resistance to therapy and facilitate the spread of metastases. Researchers of the Molecular Oncology group, led by Prof Andrea Alimonti, Principal Investigator at VIMM and the Oncological Research Institute (IOR) of Bellinzona, and Associate Investigator at VIMM Dr Monica Montopoli began with this idea to develop a new approach to treating prostate cancer.

Taking advantage of a broad chemogenomic screening platform previously developed in the laboratory, researchers identified small molecules capable of triggering senescence in prostate cancer cells, thanks to a screening library of more than 90,000 compounds. Researchers aimed at identifying the retinoic acid receptor agonists, a powerful class of compounds capable of inducing senescence, to stop the cell proliferation of prostate cancer in combination with docetaxel to enhance the anti-tumor effect of the individual compounds. In addition to this, the researchers were able to verify that the combination of adapalene with docetaxel blocks the emergence of therapeutic resistance, which prevents the formation of metastases while activating a powerful anti-tumor immune response.

"Our discovery offers innovative strategies to enhance existing therapies", explains Alimonti. "This combination could promote greater migration of NK cells also in other types of tumors, further improving their anti-tumor activity.”

[summary] => [format] => 2 [safe_value] =>

Prostate cancer is the second leading cause of cancer-related mortality among men worldwide. Although much research concentrates on this form of cancer, the mechanisms underlying resistance to therapy remain poorly understood. Cellular senescence can exert dual effects in tumors, either suppressing or promoting tumor progression. Consequently, the clinical challenge lies in developing therapies that safely enhance senescence in cancer, favoring tumor-suppressive factors.

The study Retinoic acid receptor activation reprograms senescence response and enhances anti-tumor activity of natural killer cells, published by researchers at the Veneto Institute of Molecular Medicine (VIMM), the University of Padua, and the Oncology Research Institute (IOR) of Bellinzona, offer an innovative approach to treating prostate cancer. The promising breakthrough involves cellular senescence and a subset of anti-tumor immune system cells known as natural killer cells (NK cells).

Cellular senescence can halt the proliferation of tumor cells but under specific circumstances, it can also promote resistance to therapy and facilitate the spread of metastases. Researchers of the Molecular Oncology group, led by Prof Andrea Alimonti, Principal Investigator at VIMM and the Oncological Research Institute (IOR) of Bellinzona, and Associate Investigator at VIMM Dr Monica Montopoli began with this idea to develop a new approach to treating prostate cancer.

Taking advantage of a broad chemogenomic screening platform previously developed in the laboratory, researchers identified small molecules capable of triggering senescence in prostate cancer cells, thanks to a screening library of more than 90,000 compounds. Researchers aimed at identifying the retinoic acid receptor agonists, a powerful class of compounds capable of inducing senescence, to stop the cell proliferation of prostate cancer in combination with docetaxel to enhance the anti-tumor effect of the individual compounds. In addition to this, the researchers were able to verify that the combination of adapalene with docetaxel blocks the emergence of therapeutic resistance, which prevents the formation of metastases while activating a powerful anti-tumor immune response.

"Our discovery offers innovative strategies to enhance existing therapies", explains Alimonti. "This combination could promote greater migration of NK cells also in other types of tumors, further improving their anti-tumor activity.”

[safe_summary] => ) ) ) [field_date_box_lancio_news] => Array ( [und] => Array ( [0] => Array ( [value] => 2024-03-11T00:00:00 [timezone] => Europe/Paris [timezone_db] => Europe/Paris [date_type] => date ) ) ) [field_etichetta_box_lancio_news] => Array ( ) [field_img_box_lancio_news] => Array ( [und] => Array ( [0] => Array ( [fid] => 128176 [uid] => 2032 [filename] => n_uomoleonardo.jpg [uri] => public://n_uomoleonardo_0.jpg [filemime] => image/jpeg [filesize] => 47059 [status] => 1 [timestamp] => 1710147247 [type] => image [field_file_image_alt_text] => Array ( ) [field_file_image_title_text] => Array ( ) [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2048 ) ) ) [metadata] => Array ( [height] => 227 [width] => 677 ) [height] => 227 [width] => 677 [alt] => man [title] => ) ) ) [field_link_alla_news] => Array ( ) [field_link_esterno_news] => Array ( [und] => Array ( [0] => Array ( [value] => [format] => [safe_value] => ) ) ) [field_pagina_associata] => Array ( ) [field_link_etichetta] => Array ( ) [field_abstract_news] => Array ( [und] => Array ( [0] => Array ( [value] => A study, carried out by research teams from the University of Padua, VIMM and the Bellinzona Research Oncology Institute at the University of Italian Switzerland, investigates a new therapeutic approach for prostate cancer [format] => [safe_value] => A study, carried out by research teams from the University of Padua, VIMM and the Bellinzona Research Oncology Institute at the University of Italian Switzerland, investigates a new therapeutic approach for prostate cancer ) ) ) [field_allegato_news] => Array ( ) [field_categorie_news] => Array ( [und] => Array ( [0] => Array ( [tid] => 2296 ) ) ) [field_pub_date] => Array ( [und] => Array ( [0] => Array ( [value] => 2024-03-11T00:00:00 [value2] => 2025-03-11T00:00:00 [timezone] => Europe/Paris [timezone_db] => Europe/Paris [date_type] => date ) ) ) [field_layout_news] => Array ( [und] => Array ( [0] => Array ( [value] => single ) ) ) [field_testo_opzionale_news] => Array ( ) [field_url_en_page] => Array ( ) [field_url_en_page_label] => Array ( ) [path] => Array ( [pathauto] => 1 ) [name] => francesca.forzan [picture] => 0 [data] => b:0; [num_revisions] => 1 [current_revision_id] => 451914 [is_current] => 1 [is_pending] => [revision_moderation] => [entity_view_prepared] => 1 ) [#items] => Array ( [0] => Array ( [value] => [format] => [safe_value] => ) ) [#formatter] => text_default [0] => Array ( [#markup] => ) ) [body] => Array ( [#theme] => field [#weight] => 0 [#title] => Body [#access] => 1 [#label_display] => hidden [#view_mode] => teaser [#language] => und [#field_name] => body [#field_type] => text_with_summary [#field_translatable] => 0 [#entity_type] => node [#bundle] => box_lancio_news [#object] => stdClass Object ( [vid] => 451914 [uid] => 2032 [title] => An Innovative Approach to Treating Prostate Cancer [log] => [status] => 1 [comment] => 0 [promote] => 1 [sticky] => 0 [nid] => 108435 [type] => box_lancio_news [language] => it [created] => 1710147247 [changed] => 1710147247 [tnid] => 0 [translate] => 0 [revision_timestamp] => 1710147247 [revision_uid] => 2032 [body] => Array ( [und] => Array ( [0] => Array ( [value] =>

Prostate cancer is the second leading cause of cancer-related mortality among men worldwide. Although much research concentrates on this form of cancer, the mechanisms underlying resistance to therapy remain poorly understood. Cellular senescence can exert dual effects in tumors, either suppressing or promoting tumor progression. Consequently, the clinical challenge lies in developing therapies that safely enhance senescence in cancer, favoring tumor-suppressive factors.

The study Retinoic acid receptor activation reprograms senescence response and enhances anti-tumor activity of natural killer cells, published by researchers at the Veneto Institute of Molecular Medicine (VIMM), the University of Padua, and the Oncology Research Institute (IOR) of Bellinzona, offer an innovative approach to treating prostate cancer. The promising breakthrough involves cellular senescence and a subset of anti-tumor immune system cells known as natural killer cells (NK cells).

Cellular senescence can halt the proliferation of tumor cells but under specific circumstances, it can also promote resistance to therapy and facilitate the spread of metastases. Researchers of the Molecular Oncology group, led by Prof Andrea Alimonti, Principal Investigator at VIMM and the Oncological Research Institute (IOR) of Bellinzona, and Associate Investigator at VIMM Dr Monica Montopoli began with this idea to develop a new approach to treating prostate cancer.

Taking advantage of a broad chemogenomic screening platform previously developed in the laboratory, researchers identified small molecules capable of triggering senescence in prostate cancer cells, thanks to a screening library of more than 90,000 compounds. Researchers aimed at identifying the retinoic acid receptor agonists, a powerful class of compounds capable of inducing senescence, to stop the cell proliferation of prostate cancer in combination with docetaxel to enhance the anti-tumor effect of the individual compounds. In addition to this, the researchers were able to verify that the combination of adapalene with docetaxel blocks the emergence of therapeutic resistance, which prevents the formation of metastases while activating a powerful anti-tumor immune response.

"Our discovery offers innovative strategies to enhance existing therapies", explains Alimonti. "This combination could promote greater migration of NK cells also in other types of tumors, further improving their anti-tumor activity.”

[summary] => [format] => 2 [safe_value] =>

Prostate cancer is the second leading cause of cancer-related mortality among men worldwide. Although much research concentrates on this form of cancer, the mechanisms underlying resistance to therapy remain poorly understood. Cellular senescence can exert dual effects in tumors, either suppressing or promoting tumor progression. Consequently, the clinical challenge lies in developing therapies that safely enhance senescence in cancer, favoring tumor-suppressive factors.

The study Retinoic acid receptor activation reprograms senescence response and enhances anti-tumor activity of natural killer cells, published by researchers at the Veneto Institute of Molecular Medicine (VIMM), the University of Padua, and the Oncology Research Institute (IOR) of Bellinzona, offer an innovative approach to treating prostate cancer. The promising breakthrough involves cellular senescence and a subset of anti-tumor immune system cells known as natural killer cells (NK cells).

Cellular senescence can halt the proliferation of tumor cells but under specific circumstances, it can also promote resistance to therapy and facilitate the spread of metastases. Researchers of the Molecular Oncology group, led by Prof Andrea Alimonti, Principal Investigator at VIMM and the Oncological Research Institute (IOR) of Bellinzona, and Associate Investigator at VIMM Dr Monica Montopoli began with this idea to develop a new approach to treating prostate cancer.

Taking advantage of a broad chemogenomic screening platform previously developed in the laboratory, researchers identified small molecules capable of triggering senescence in prostate cancer cells, thanks to a screening library of more than 90,000 compounds. Researchers aimed at identifying the retinoic acid receptor agonists, a powerful class of compounds capable of inducing senescence, to stop the cell proliferation of prostate cancer in combination with docetaxel to enhance the anti-tumor effect of the individual compounds. In addition to this, the researchers were able to verify that the combination of adapalene with docetaxel blocks the emergence of therapeutic resistance, which prevents the formation of metastases while activating a powerful anti-tumor immune response.

"Our discovery offers innovative strategies to enhance existing therapies", explains Alimonti. "This combination could promote greater migration of NK cells also in other types of tumors, further improving their anti-tumor activity.”

[safe_summary] => ) ) ) [field_date_box_lancio_news] => Array ( [und] => Array ( [0] => Array ( [value] => 2024-03-11T00:00:00 [timezone] => Europe/Paris [timezone_db] => Europe/Paris [date_type] => date ) ) ) [field_etichetta_box_lancio_news] => Array ( ) [field_img_box_lancio_news] => Array ( [und] => Array ( [0] => Array ( [fid] => 128176 [uid] => 2032 [filename] => n_uomoleonardo.jpg [uri] => public://n_uomoleonardo_0.jpg [filemime] => image/jpeg [filesize] => 47059 [status] => 1 [timestamp] => 1710147247 [type] => image [field_file_image_alt_text] => Array ( ) [field_file_image_title_text] => Array ( ) [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2048 ) ) ) [metadata] => Array ( [height] => 227 [width] => 677 ) [height] => 227 [width] => 677 [alt] => man [title] => ) ) ) [field_link_alla_news] => Array ( ) [field_link_esterno_news] => Array ( [und] => Array ( [0] => Array ( [value] => [format] => [safe_value] => ) ) ) [field_pagina_associata] => Array ( ) [field_link_etichetta] => Array ( ) [field_abstract_news] => Array ( [und] => Array ( [0] => Array ( [value] => A study, carried out by research teams from the University of Padua, VIMM and the Bellinzona Research Oncology Institute at the University of Italian Switzerland, investigates a new therapeutic approach for prostate cancer [format] => [safe_value] => A study, carried out by research teams from the University of Padua, VIMM and the Bellinzona Research Oncology Institute at the University of Italian Switzerland, investigates a new therapeutic approach for prostate cancer ) ) ) [field_allegato_news] => Array ( ) [field_categorie_news] => Array ( [und] => Array ( [0] => Array ( [tid] => 2296 ) ) ) [field_pub_date] => Array ( [und] => Array ( [0] => Array ( [value] => 2024-03-11T00:00:00 [value2] => 2025-03-11T00:00:00 [timezone] => Europe/Paris [timezone_db] => Europe/Paris [date_type] => date ) ) ) [field_layout_news] => Array ( [und] => Array ( [0] => Array ( [value] => single ) ) ) [field_testo_opzionale_news] => Array ( ) [field_url_en_page] => Array ( ) [field_url_en_page_label] => Array ( ) [path] => Array ( [pathauto] => 1 ) [name] => francesca.forzan [picture] => 0 [data] => b:0; [num_revisions] => 1 [current_revision_id] => 451914 [is_current] => 1 [is_pending] => [revision_moderation] => [entity_view_prepared] => 1 ) [#items] => Array ( [0] => Array ( [value] =>

Prostate cancer is the second leading cause of cancer-related mortality among men worldwide. Although much research concentrates on this form of cancer, the mechanisms underlying resistance to therapy remain poorly understood. Cellular senescence can exert dual effects in tumors, either suppressing or promoting tumor progression. Consequently, the clinical challenge lies in developing therapies that safely enhance senescence in cancer, favoring tumor-suppressive factors.

The study Retinoic acid receptor activation reprograms senescence response and enhances anti-tumor activity of natural killer cells, published by researchers at the Veneto Institute of Molecular Medicine (VIMM), the University of Padua, and the Oncology Research Institute (IOR) of Bellinzona, offer an innovative approach to treating prostate cancer. The promising breakthrough involves cellular senescence and a subset of anti-tumor immune system cells known as natural killer cells (NK cells).

Cellular senescence can halt the proliferation of tumor cells but under specific circumstances, it can also promote resistance to therapy and facilitate the spread of metastases. Researchers of the Molecular Oncology group, led by Prof Andrea Alimonti, Principal Investigator at VIMM and the Oncological Research Institute (IOR) of Bellinzona, and Associate Investigator at VIMM Dr Monica Montopoli began with this idea to develop a new approach to treating prostate cancer.

Taking advantage of a broad chemogenomic screening platform previously developed in the laboratory, researchers identified small molecules capable of triggering senescence in prostate cancer cells, thanks to a screening library of more than 90,000 compounds. Researchers aimed at identifying the retinoic acid receptor agonists, a powerful class of compounds capable of inducing senescence, to stop the cell proliferation of prostate cancer in combination with docetaxel to enhance the anti-tumor effect of the individual compounds. In addition to this, the researchers were able to verify that the combination of adapalene with docetaxel blocks the emergence of therapeutic resistance, which prevents the formation of metastases while activating a powerful anti-tumor immune response.

"Our discovery offers innovative strategies to enhance existing therapies", explains Alimonti. "This combination could promote greater migration of NK cells also in other types of tumors, further improving their anti-tumor activity.”

[summary] => [format] => 2 [safe_value] =>

Prostate cancer is the second leading cause of cancer-related mortality among men worldwide. Although much research concentrates on this form of cancer, the mechanisms underlying resistance to therapy remain poorly understood. Cellular senescence can exert dual effects in tumors, either suppressing or promoting tumor progression. Consequently, the clinical challenge lies in developing therapies that safely enhance senescence in cancer, favoring tumor-suppressive factors.

The study Retinoic acid receptor activation reprograms senescence response and enhances anti-tumor activity of natural killer cells, published by researchers at the Veneto Institute of Molecular Medicine (VIMM), the University of Padua, and the Oncology Research Institute (IOR) of Bellinzona, offer an innovative approach to treating prostate cancer. The promising breakthrough involves cellular senescence and a subset of anti-tumor immune system cells known as natural killer cells (NK cells).

Cellular senescence can halt the proliferation of tumor cells but under specific circumstances, it can also promote resistance to therapy and facilitate the spread of metastases. Researchers of the Molecular Oncology group, led by Prof Andrea Alimonti, Principal Investigator at VIMM and the Oncological Research Institute (IOR) of Bellinzona, and Associate Investigator at VIMM Dr Monica Montopoli began with this idea to develop a new approach to treating prostate cancer.

Taking advantage of a broad chemogenomic screening platform previously developed in the laboratory, researchers identified small molecules capable of triggering senescence in prostate cancer cells, thanks to a screening library of more than 90,000 compounds. Researchers aimed at identifying the retinoic acid receptor agonists, a powerful class of compounds capable of inducing senescence, to stop the cell proliferation of prostate cancer in combination with docetaxel to enhance the anti-tumor effect of the individual compounds. In addition to this, the researchers were able to verify that the combination of adapalene with docetaxel blocks the emergence of therapeutic resistance, which prevents the formation of metastases while activating a powerful anti-tumor immune response.

"Our discovery offers innovative strategies to enhance existing therapies", explains Alimonti. "This combination could promote greater migration of NK cells also in other types of tumors, further improving their anti-tumor activity.”

[safe_summary] => ) ) [#formatter] => text_summary_or_trimmed [0] => Array ( [#markup] =>

Prostate cancer is the second leading cause of cancer-related mortality among men worldwide. Although much research concentrates on this form of cancer, the mechanisms underlying resistance to therapy remain poorly understood. Cellular senescence can exert dual effects in tumors, either suppressing or promoting tumor progression. Consequently, the clinical challenge lies in developing therapies that safely enhance senescence in cancer, favoring tumor-suppressive factors.

) ) [field_img_box_lancio_news] => Array ( [#theme] => field [#weight] => 0 [#title] => Immagine [#access] => 1 [#label_display] => above [#view_mode] => teaser [#language] => und [#field_name] => field_img_box_lancio_news [#field_type] => image [#field_translatable] => 0 [#entity_type] => node [#bundle] => box_lancio_news [#object] => stdClass Object ( [vid] => 451914 [uid] => 2032 [title] => An Innovative Approach to Treating Prostate Cancer [log] => [status] => 1 [comment] => 0 [promote] => 1 [sticky] => 0 [nid] => 108435 [type] => box_lancio_news [language] => it [created] => 1710147247 [changed] => 1710147247 [tnid] => 0 [translate] => 0 [revision_timestamp] => 1710147247 [revision_uid] => 2032 [body] => Array ( [und] => Array ( [0] => Array ( [value] =>

Prostate cancer is the second leading cause of cancer-related mortality among men worldwide. Although much research concentrates on this form of cancer, the mechanisms underlying resistance to therapy remain poorly understood. Cellular senescence can exert dual effects in tumors, either suppressing or promoting tumor progression. Consequently, the clinical challenge lies in developing therapies that safely enhance senescence in cancer, favoring tumor-suppressive factors.

The study Retinoic acid receptor activation reprograms senescence response and enhances anti-tumor activity of natural killer cells, published by researchers at the Veneto Institute of Molecular Medicine (VIMM), the University of Padua, and the Oncology Research Institute (IOR) of Bellinzona, offer an innovative approach to treating prostate cancer. The promising breakthrough involves cellular senescence and a subset of anti-tumor immune system cells known as natural killer cells (NK cells).

Cellular senescence can halt the proliferation of tumor cells but under specific circumstances, it can also promote resistance to therapy and facilitate the spread of metastases. Researchers of the Molecular Oncology group, led by Prof Andrea Alimonti, Principal Investigator at VIMM and the Oncological Research Institute (IOR) of Bellinzona, and Associate Investigator at VIMM Dr Monica Montopoli began with this idea to develop a new approach to treating prostate cancer.

Taking advantage of a broad chemogenomic screening platform previously developed in the laboratory, researchers identified small molecules capable of triggering senescence in prostate cancer cells, thanks to a screening library of more than 90,000 compounds. Researchers aimed at identifying the retinoic acid receptor agonists, a powerful class of compounds capable of inducing senescence, to stop the cell proliferation of prostate cancer in combination with docetaxel to enhance the anti-tumor effect of the individual compounds. In addition to this, the researchers were able to verify that the combination of adapalene with docetaxel blocks the emergence of therapeutic resistance, which prevents the formation of metastases while activating a powerful anti-tumor immune response.

"Our discovery offers innovative strategies to enhance existing therapies", explains Alimonti. "This combination could promote greater migration of NK cells also in other types of tumors, further improving their anti-tumor activity.”

[summary] => [format] => 2 [safe_value] =>

Prostate cancer is the second leading cause of cancer-related mortality among men worldwide. Although much research concentrates on this form of cancer, the mechanisms underlying resistance to therapy remain poorly understood. Cellular senescence can exert dual effects in tumors, either suppressing or promoting tumor progression. Consequently, the clinical challenge lies in developing therapies that safely enhance senescence in cancer, favoring tumor-suppressive factors.

The study Retinoic acid receptor activation reprograms senescence response and enhances anti-tumor activity of natural killer cells, published by researchers at the Veneto Institute of Molecular Medicine (VIMM), the University of Padua, and the Oncology Research Institute (IOR) of Bellinzona, offer an innovative approach to treating prostate cancer. The promising breakthrough involves cellular senescence and a subset of anti-tumor immune system cells known as natural killer cells (NK cells).

Cellular senescence can halt the proliferation of tumor cells but under specific circumstances, it can also promote resistance to therapy and facilitate the spread of metastases. Researchers of the Molecular Oncology group, led by Prof Andrea Alimonti, Principal Investigator at VIMM and the Oncological Research Institute (IOR) of Bellinzona, and Associate Investigator at VIMM Dr Monica Montopoli began with this idea to develop a new approach to treating prostate cancer.

Taking advantage of a broad chemogenomic screening platform previously developed in the laboratory, researchers identified small molecules capable of triggering senescence in prostate cancer cells, thanks to a screening library of more than 90,000 compounds. Researchers aimed at identifying the retinoic acid receptor agonists, a powerful class of compounds capable of inducing senescence, to stop the cell proliferation of prostate cancer in combination with docetaxel to enhance the anti-tumor effect of the individual compounds. In addition to this, the researchers were able to verify that the combination of adapalene with docetaxel blocks the emergence of therapeutic resistance, which prevents the formation of metastases while activating a powerful anti-tumor immune response.

"Our discovery offers innovative strategies to enhance existing therapies", explains Alimonti. "This combination could promote greater migration of NK cells also in other types of tumors, further improving their anti-tumor activity.”

[safe_summary] => ) ) ) [field_date_box_lancio_news] => Array ( [und] => Array ( [0] => Array ( [value] => 2024-03-11T00:00:00 [timezone] => Europe/Paris [timezone_db] => Europe/Paris [date_type] => date ) ) ) [field_etichetta_box_lancio_news] => Array ( ) [field_img_box_lancio_news] => Array ( [und] => Array ( [0] => Array ( [fid] => 128176 [uid] => 2032 [filename] => n_uomoleonardo.jpg [uri] => public://n_uomoleonardo_0.jpg [filemime] => image/jpeg [filesize] => 47059 [status] => 1 [timestamp] => 1710147247 [type] => image [field_file_image_alt_text] => Array ( ) [field_file_image_title_text] => Array ( ) [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2048 ) ) ) [metadata] => Array ( [height] => 227 [width] => 677 ) [height] => 227 [width] => 677 [alt] => man [title] => ) ) ) [field_link_alla_news] => Array ( ) [field_link_esterno_news] => Array ( [und] => Array ( [0] => Array ( [value] => [format] => [safe_value] => ) ) ) [field_pagina_associata] => Array ( ) [field_link_etichetta] => Array ( ) [field_abstract_news] => Array ( [und] => Array ( [0] => Array ( [value] => A study, carried out by research teams from the University of Padua, VIMM and the Bellinzona Research Oncology Institute at the University of Italian Switzerland, investigates a new therapeutic approach for prostate cancer [format] => [safe_value] => A study, carried out by research teams from the University of Padua, VIMM and the Bellinzona Research Oncology Institute at the University of Italian Switzerland, investigates a new therapeutic approach for prostate cancer ) ) ) [field_allegato_news] => Array ( ) [field_categorie_news] => Array ( [und] => Array ( [0] => Array ( [tid] => 2296 ) ) ) [field_pub_date] => Array ( [und] => Array ( [0] => Array ( [value] => 2024-03-11T00:00:00 [value2] => 2025-03-11T00:00:00 [timezone] => Europe/Paris [timezone_db] => Europe/Paris [date_type] => date ) ) ) [field_layout_news] => Array ( [und] => Array ( [0] => Array ( [value] => single ) ) ) [field_testo_opzionale_news] => Array ( ) [field_url_en_page] => Array ( ) [field_url_en_page_label] => Array ( ) [path] => Array ( [pathauto] => 1 ) [name] => francesca.forzan [picture] => 0 [data] => b:0; [num_revisions] => 1 [current_revision_id] => 451914 [is_current] => 1 [is_pending] => [revision_moderation] => [entity_view_prepared] => 1 ) [#items] => Array ( [0] => Array ( [fid] => 128176 [uid] => 2032 [filename] => n_uomoleonardo.jpg [uri] => public://n_uomoleonardo_0.jpg [filemime] => image/jpeg [filesize] => 47059 [status] => 1 [timestamp] => 1710147247 [type] => image [field_file_image_alt_text] => Array ( ) [field_file_image_title_text] => Array ( ) [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2048 ) ) ) [metadata] => Array ( [height] => 227 [width] => 677 ) [height] => 227 [width] => 677 [alt] => man [title] => ) ) [#formatter] => image [0] => Array ( [#theme] => image_formatter [#item] => Array ( [fid] => 128176 [uid] => 2032 [filename] => n_uomoleonardo.jpg [uri] => public://n_uomoleonardo_0.jpg [filemime] => image/jpeg [filesize] => 47059 [status] => 1 [timestamp] => 1710147247 [type] => image [field_file_image_alt_text] => Array ( ) [field_file_image_title_text] => Array ( ) [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2048 ) ) ) [metadata] => Array ( [height] => 227 [width] => 677 ) [height] => 227 [width] => 677 [alt] => man [title] => ) [#image_style] => [#path] => ) ) [field_abstract_news] => Array ( [#theme] => field [#weight] => 0 [#title] => Abstract [#access] => 1 [#label_display] => above [#view_mode] => teaser [#language] => und [#field_name] => field_abstract_news [#field_type] => text_long [#field_translatable] => 0 [#entity_type] => node [#bundle] => box_lancio_news [#object] => stdClass Object ( [vid] => 451914 [uid] => 2032 [title] => An Innovative Approach to Treating Prostate Cancer [log] => [status] => 1 [comment] => 0 [promote] => 1 [sticky] => 0 [nid] => 108435 [type] => box_lancio_news [language] => it [created] => 1710147247 [changed] => 1710147247 [tnid] => 0 [translate] => 0 [revision_timestamp] => 1710147247 [revision_uid] => 2032 [body] => Array ( [und] => Array ( [0] => Array ( [value] =>

Prostate cancer is the second leading cause of cancer-related mortality among men worldwide. Although much research concentrates on this form of cancer, the mechanisms underlying resistance to therapy remain poorly understood. Cellular senescence can exert dual effects in tumors, either suppressing or promoting tumor progression. Consequently, the clinical challenge lies in developing therapies that safely enhance senescence in cancer, favoring tumor-suppressive factors.

The study Retinoic acid receptor activation reprograms senescence response and enhances anti-tumor activity of natural killer cells, published by researchers at the Veneto Institute of Molecular Medicine (VIMM), the University of Padua, and the Oncology Research Institute (IOR) of Bellinzona, offer an innovative approach to treating prostate cancer. The promising breakthrough involves cellular senescence and a subset of anti-tumor immune system cells known as natural killer cells (NK cells).

Cellular senescence can halt the proliferation of tumor cells but under specific circumstances, it can also promote resistance to therapy and facilitate the spread of metastases. Researchers of the Molecular Oncology group, led by Prof Andrea Alimonti, Principal Investigator at VIMM and the Oncological Research Institute (IOR) of Bellinzona, and Associate Investigator at VIMM Dr Monica Montopoli began with this idea to develop a new approach to treating prostate cancer.

Taking advantage of a broad chemogenomic screening platform previously developed in the laboratory, researchers identified small molecules capable of triggering senescence in prostate cancer cells, thanks to a screening library of more than 90,000 compounds. Researchers aimed at identifying the retinoic acid receptor agonists, a powerful class of compounds capable of inducing senescence, to stop the cell proliferation of prostate cancer in combination with docetaxel to enhance the anti-tumor effect of the individual compounds. In addition to this, the researchers were able to verify that the combination of adapalene with docetaxel blocks the emergence of therapeutic resistance, which prevents the formation of metastases while activating a powerful anti-tumor immune response.

"Our discovery offers innovative strategies to enhance existing therapies", explains Alimonti. "This combination could promote greater migration of NK cells also in other types of tumors, further improving their anti-tumor activity.”

[summary] => [format] => 2 [safe_value] =>

Prostate cancer is the second leading cause of cancer-related mortality among men worldwide. Although much research concentrates on this form of cancer, the mechanisms underlying resistance to therapy remain poorly understood. Cellular senescence can exert dual effects in tumors, either suppressing or promoting tumor progression. Consequently, the clinical challenge lies in developing therapies that safely enhance senescence in cancer, favoring tumor-suppressive factors.

The study Retinoic acid receptor activation reprograms senescence response and enhances anti-tumor activity of natural killer cells, published by researchers at the Veneto Institute of Molecular Medicine (VIMM), the University of Padua, and the Oncology Research Institute (IOR) of Bellinzona, offer an innovative approach to treating prostate cancer. The promising breakthrough involves cellular senescence and a subset of anti-tumor immune system cells known as natural killer cells (NK cells).

Cellular senescence can halt the proliferation of tumor cells but under specific circumstances, it can also promote resistance to therapy and facilitate the spread of metastases. Researchers of the Molecular Oncology group, led by Prof Andrea Alimonti, Principal Investigator at VIMM and the Oncological Research Institute (IOR) of Bellinzona, and Associate Investigator at VIMM Dr Monica Montopoli began with this idea to develop a new approach to treating prostate cancer.

Taking advantage of a broad chemogenomic screening platform previously developed in the laboratory, researchers identified small molecules capable of triggering senescence in prostate cancer cells, thanks to a screening library of more than 90,000 compounds. Researchers aimed at identifying the retinoic acid receptor agonists, a powerful class of compounds capable of inducing senescence, to stop the cell proliferation of prostate cancer in combination with docetaxel to enhance the anti-tumor effect of the individual compounds. In addition to this, the researchers were able to verify that the combination of adapalene with docetaxel blocks the emergence of therapeutic resistance, which prevents the formation of metastases while activating a powerful anti-tumor immune response.

"Our discovery offers innovative strategies to enhance existing therapies", explains Alimonti. "This combination could promote greater migration of NK cells also in other types of tumors, further improving their anti-tumor activity.”

[safe_summary] => ) ) ) [field_date_box_lancio_news] => Array ( [und] => Array ( [0] => Array ( [value] => 2024-03-11T00:00:00 [timezone] => Europe/Paris [timezone_db] => Europe/Paris [date_type] => date ) ) ) [field_etichetta_box_lancio_news] => Array ( ) [field_img_box_lancio_news] => Array ( [und] => Array ( [0] => Array ( [fid] => 128176 [uid] => 2032 [filename] => n_uomoleonardo.jpg [uri] => public://n_uomoleonardo_0.jpg [filemime] => image/jpeg [filesize] => 47059 [status] => 1 [timestamp] => 1710147247 [type] => image [field_file_image_alt_text] => Array ( ) [field_file_image_title_text] => Array ( ) [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2048 ) ) ) [metadata] => Array ( [height] => 227 [width] => 677 ) [height] => 227 [width] => 677 [alt] => man [title] => ) ) ) [field_link_alla_news] => Array ( ) [field_link_esterno_news] => Array ( [und] => Array ( [0] => Array ( [value] => [format] => [safe_value] => ) ) ) [field_pagina_associata] => Array ( ) [field_link_etichetta] => Array ( ) [field_abstract_news] => Array ( [und] => Array ( [0] => Array ( [value] => A study, carried out by research teams from the University of Padua, VIMM and the Bellinzona Research Oncology Institute at the University of Italian Switzerland, investigates a new therapeutic approach for prostate cancer [format] => [safe_value] => A study, carried out by research teams from the University of Padua, VIMM and the Bellinzona Research Oncology Institute at the University of Italian Switzerland, investigates a new therapeutic approach for prostate cancer ) ) ) [field_allegato_news] => Array ( ) [field_categorie_news] => Array ( [und] => Array ( [0] => Array ( [tid] => 2296 ) ) ) [field_pub_date] => Array ( [und] => Array ( [0] => Array ( [value] => 2024-03-11T00:00:00 [value2] => 2025-03-11T00:00:00 [timezone] => Europe/Paris [timezone_db] => Europe/Paris [date_type] => date ) ) ) [field_layout_news] => Array ( [und] => Array ( [0] => Array ( [value] => single ) ) ) [field_testo_opzionale_news] => Array ( ) [field_url_en_page] => Array ( ) [field_url_en_page_label] => Array ( ) [path] => Array ( [pathauto] => 1 ) [name] => francesca.forzan [picture] => 0 [data] => b:0; [num_revisions] => 1 [current_revision_id] => 451914 [is_current] => 1 [is_pending] => [revision_moderation] => [entity_view_prepared] => 1 ) [#items] => Array ( [0] => Array ( [value] => A study, carried out by research teams from the University of Padua, VIMM and the Bellinzona Research Oncology Institute at the University of Italian Switzerland, investigates a new therapeutic approach for prostate cancer [format] => [safe_value] => A study, carried out by research teams from the University of Padua, VIMM and the Bellinzona Research Oncology Institute at the University of Italian Switzerland, investigates a new therapeutic approach for prostate cancer ) ) [#formatter] => text_default [0] => Array ( [#markup] => A study, carried out by research teams from the University of Padua, VIMM and the Bellinzona Research Oncology Institute at the University of Italian Switzerland, investigates a new therapeutic approach for prostate cancer ) ) [links] => Array ( [#theme] => links__node [#pre_render] => Array ( [0] => drupal_pre_render_links ) [#attributes] => Array ( [class] => Array ( [0] => links [1] => inline ) ) [node] => Array ( [#theme] => links__node__node [#links] => Array ( [node-readmore] => Array ( [title] => Read more about An Innovative Approach to Treating Prostate Cancer [href] => node/108435 [html] => 1 [attributes] => Array ( [rel] => tag [title] => An Innovative Approach to Treating Prostate Cancer ) ) ) [#attributes] => Array ( [class] => Array ( [0] => links [1] => inline ) ) ) ) [field_date_box_lancio_news] => Array ( [#theme] => field [#weight] => 1 [#title] => Data [#access] => 1 [#label_display] => above [#view_mode] => teaser [#language] => und [#field_name] => field_date_box_lancio_news [#field_type] => date [#field_translatable] => 0 [#entity_type] => node [#bundle] => box_lancio_news [#object] => stdClass Object ( [vid] => 451914 [uid] => 2032 [title] => An Innovative Approach to Treating Prostate Cancer [log] => [status] => 1 [comment] => 0 [promote] => 1 [sticky] => 0 [nid] => 108435 [type] => box_lancio_news [language] => it [created] => 1710147247 [changed] => 1710147247 [tnid] => 0 [translate] => 0 [revision_timestamp] => 1710147247 [revision_uid] => 2032 [body] => Array ( [und] => Array ( [0] => Array ( [value] =>

Prostate cancer is the second leading cause of cancer-related mortality among men worldwide. Although much research concentrates on this form of cancer, the mechanisms underlying resistance to therapy remain poorly understood. Cellular senescence can exert dual effects in tumors, either suppressing or promoting tumor progression. Consequently, the clinical challenge lies in developing therapies that safely enhance senescence in cancer, favoring tumor-suppressive factors.

The study Retinoic acid receptor activation reprograms senescence response and enhances anti-tumor activity of natural killer cells, published by researchers at the Veneto Institute of Molecular Medicine (VIMM), the University of Padua, and the Oncology Research Institute (IOR) of Bellinzona, offer an innovative approach to treating prostate cancer. The promising breakthrough involves cellular senescence and a subset of anti-tumor immune system cells known as natural killer cells (NK cells).

Cellular senescence can halt the proliferation of tumor cells but under specific circumstances, it can also promote resistance to therapy and facilitate the spread of metastases. Researchers of the Molecular Oncology group, led by Prof Andrea Alimonti, Principal Investigator at VIMM and the Oncological Research Institute (IOR) of Bellinzona, and Associate Investigator at VIMM Dr Monica Montopoli began with this idea to develop a new approach to treating prostate cancer.

Taking advantage of a broad chemogenomic screening platform previously developed in the laboratory, researchers identified small molecules capable of triggering senescence in prostate cancer cells, thanks to a screening library of more than 90,000 compounds. Researchers aimed at identifying the retinoic acid receptor agonists, a powerful class of compounds capable of inducing senescence, to stop the cell proliferation of prostate cancer in combination with docetaxel to enhance the anti-tumor effect of the individual compounds. In addition to this, the researchers were able to verify that the combination of adapalene with docetaxel blocks the emergence of therapeutic resistance, which prevents the formation of metastases while activating a powerful anti-tumor immune response.

"Our discovery offers innovative strategies to enhance existing therapies", explains Alimonti. "This combination could promote greater migration of NK cells also in other types of tumors, further improving their anti-tumor activity.”

[summary] => [format] => 2 [safe_value] =>

Prostate cancer is the second leading cause of cancer-related mortality among men worldwide. Although much research concentrates on this form of cancer, the mechanisms underlying resistance to therapy remain poorly understood. Cellular senescence can exert dual effects in tumors, either suppressing or promoting tumor progression. Consequently, the clinical challenge lies in developing therapies that safely enhance senescence in cancer, favoring tumor-suppressive factors.

The study Retinoic acid receptor activation reprograms senescence response and enhances anti-tumor activity of natural killer cells, published by researchers at the Veneto Institute of Molecular Medicine (VIMM), the University of Padua, and the Oncology Research Institute (IOR) of Bellinzona, offer an innovative approach to treating prostate cancer. The promising breakthrough involves cellular senescence and a subset of anti-tumor immune system cells known as natural killer cells (NK cells).

Cellular senescence can halt the proliferation of tumor cells but under specific circumstances, it can also promote resistance to therapy and facilitate the spread of metastases. Researchers of the Molecular Oncology group, led by Prof Andrea Alimonti, Principal Investigator at VIMM and the Oncological Research Institute (IOR) of Bellinzona, and Associate Investigator at VIMM Dr Monica Montopoli began with this idea to develop a new approach to treating prostate cancer.

Taking advantage of a broad chemogenomic screening platform previously developed in the laboratory, researchers identified small molecules capable of triggering senescence in prostate cancer cells, thanks to a screening library of more than 90,000 compounds. Researchers aimed at identifying the retinoic acid receptor agonists, a powerful class of compounds capable of inducing senescence, to stop the cell proliferation of prostate cancer in combination with docetaxel to enhance the anti-tumor effect of the individual compounds. In addition to this, the researchers were able to verify that the combination of adapalene with docetaxel blocks the emergence of therapeutic resistance, which prevents the formation of metastases while activating a powerful anti-tumor immune response.

"Our discovery offers innovative strategies to enhance existing therapies", explains Alimonti. "This combination could promote greater migration of NK cells also in other types of tumors, further improving their anti-tumor activity.”

[safe_summary] => ) ) ) [field_date_box_lancio_news] => Array ( [und] => Array ( [0] => Array ( [value] => 2024-03-11T00:00:00 [timezone] => Europe/Paris [timezone_db] => Europe/Paris [date_type] => date ) ) ) [field_etichetta_box_lancio_news] => Array ( ) [field_img_box_lancio_news] => Array ( [und] => Array ( [0] => Array ( [fid] => 128176 [uid] => 2032 [filename] => n_uomoleonardo.jpg [uri] => public://n_uomoleonardo_0.jpg [filemime] => image/jpeg [filesize] => 47059 [status] => 1 [timestamp] => 1710147247 [type] => image [field_file_image_alt_text] => Array ( ) [field_file_image_title_text] => Array ( ) [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2048 ) ) ) [metadata] => Array ( [height] => 227 [width] => 677 ) [height] => 227 [width] => 677 [alt] => man [title] => ) ) ) [field_link_alla_news] => Array ( ) [field_link_esterno_news] => Array ( [und] => Array ( [0] => Array ( [value] => [format] => [safe_value] => ) ) ) [field_pagina_associata] => Array ( ) [field_link_etichetta] => Array ( ) [field_abstract_news] => Array ( [und] => Array ( [0] => Array ( [value] => A study, carried out by research teams from the University of Padua, VIMM and the Bellinzona Research Oncology Institute at the University of Italian Switzerland, investigates a new therapeutic approach for prostate cancer [format] => [safe_value] => A study, carried out by research teams from the University of Padua, VIMM and the Bellinzona Research Oncology Institute at the University of Italian Switzerland, investigates a new therapeutic approach for prostate cancer ) ) ) [field_allegato_news] => Array ( ) [field_categorie_news] => Array ( [und] => Array ( [0] => Array ( [tid] => 2296 ) ) ) [field_pub_date] => Array ( [und] => Array ( [0] => Array ( [value] => 2024-03-11T00:00:00 [value2] => 2025-03-11T00:00:00 [timezone] => Europe/Paris [timezone_db] => Europe/Paris [date_type] => date ) ) ) [field_layout_news] => Array ( [und] => Array ( [0] => Array ( [value] => single ) ) ) [field_testo_opzionale_news] => Array ( ) [field_url_en_page] => Array ( ) [field_url_en_page_label] => Array ( ) [path] => Array ( [pathauto] => 1 ) [name] => francesca.forzan [picture] => 0 [data] => b:0; [num_revisions] => 1 [current_revision_id] => 451914 [is_current] => 1 [is_pending] => [revision_moderation] => [entity_view_prepared] => 1 ) [#items] => Array ( [0] => Array ( [value] => 2024-03-11T00:00:00 [timezone] => Europe/Paris [timezone_db] => Europe/Paris [date_type] => date ) ) [#formatter] => date_default [0] => Array ( [#markup] => Lun, 11/03/2024 ) ) )

Measuring Entropy Production Rates. A Unipd Study

Array ( [field_link_esterno_news] => Array ( [#theme] => field [#weight] => -1 [#title] => Link esterno news [#access] => 1 [#label_display] => above [#view_mode] => teaser [#language] => und [#field_name] => field_link_esterno_news [#field_type] => text_long [#field_translatable] => 0 [#entity_type] => node [#bundle] => box_lancio_news [#object] => stdClass Object ( [vid] => 451913 [uid] => 2032 [title] => Measuring Entropy Production Rates. A Unipd Study [log] => [status] => 1 [comment] => 0 [promote] => 1 [sticky] => 0 [nid] => 108434 [type] => box_lancio_news [language] => it [created] => 1710146804 [changed] => 1710146804 [tnid] => 0 [translate] => 0 [revision_timestamp] => 1710146804 [revision_uid] => 2032 [body] => Array ( [und] => Array ( [0] => Array ( [value] =>

Researchers from the universities of Barcelona and Padua have developed a revolutionary methodology for measuring entropy production on dimensions one million times smaller than one centimeter. With affiliations from Universität Göttingen and Universidad Complutense, the Variance sum rule for entropy production study was published in the international peer-reviewed journal Science.

Despite many efforts, measuring entropy production at the nanoscale remains challenging. This study links entropy production to the flow of heat across the surface of the red blood cells that dissipates energy in the diluted fluid. Using precise calorimetry measurements, the result obtained is a million billion smaller than one calorie per second - a plate of pasta is equivalent to around 250 calories.

Operationally, the research teams detected heat flow resulting from active metabolic forces within red blood cells by observing the emerging flickering on their cell membrane. This flickering is the result of the incessant movement of molecular motors, the molecules that consume sugar to restructure cells.

"Heat is a symptom of cell health, and this finding could open up new ways to determine tissue health," explains lead researcher Professor Felix Ritort, Institute of Nanoscience and Nanotechnology, University of Barcelona. He adds, "Characterizing the entropy production in living systems is crucial for understanding the efficiency of energy conversion processes

[summary] => [format] => 2 [safe_value] =>

Researchers from the universities of Barcelona and Padua have developed a revolutionary methodology for measuring entropy production on dimensions one million times smaller than one centimeter. With affiliations from Universität Göttingen and Universidad Complutense, the Variance sum rule for entropy production study was published in the international peer-reviewed journal Science.

Despite many efforts, measuring entropy production at the nanoscale remains challenging. This study links entropy production to the flow of heat across the surface of the red blood cells that dissipates energy in the diluted fluid. Using precise calorimetry measurements, the result obtained is a million billion smaller than one calorie per second - a plate of pasta is equivalent to around 250 calories.

Operationally, the research teams detected heat flow resulting from active metabolic forces within red blood cells by observing the emerging flickering on their cell membrane. This flickering is the result of the incessant movement of molecular motors, the molecules that consume sugar to restructure cells.

"Heat is a symptom of cell health, and this finding could open up new ways to determine tissue health," explains lead researcher Professor Felix Ritort, Institute of Nanoscience and Nanotechnology, University of Barcelona. He adds, "Characterizing the entropy production in living systems is crucial for understanding the efficiency of energy conversion processes

[safe_summary] => ) ) ) [field_date_box_lancio_news] => Array ( [und] => Array ( [0] => Array ( [value] => 2024-03-11T00:00:00 [timezone] => Europe/Paris [timezone_db] => Europe/Paris [date_type] => date ) ) ) [field_etichetta_box_lancio_news] => Array ( ) [field_img_box_lancio_news] => Array ( [und] => Array ( [0] => Array ( [fid] => 128175 [uid] => 2032 [filename] => Immagine generata dall'intelligenza artificiale con l'evocazione di un globulo rosso che dissipa calore nell'ambiente.jpg [uri] => public://Immagine generata dall'intelligenza artificiale con l'evocazione di un globulo rosso che dissipa calore nell'ambiente_0.jpg [filemime] => image/jpeg [filesize] => 34606 [status] => 1 [timestamp] => 1710146804 [type] => image [field_file_image_alt_text] => Array ( ) [field_file_image_title_text] => Array ( ) [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2048 ) ) ) [metadata] => Array ( [height] => 227 [width] => 677 ) [height] => 227 [width] => 677 [alt] => globul [title] => ) ) ) [field_link_alla_news] => Array ( ) [field_link_esterno_news] => Array ( [und] => Array ( [0] => Array ( [value] => [format] => [safe_value] => ) ) ) [field_pagina_associata] => Array ( ) [field_link_etichetta] => Array ( ) [field_abstract_news] => Array ( [und] => Array ( [0] => Array ( [value] => Researchers from the universities of Barcelona and Padua have developed a revolutionary methodology for measuring entropy production on dimensions one million times smaller than one centimeter [format] => [safe_value] => Researchers from the universities of Barcelona and Padua have developed a revolutionary methodology for measuring entropy production on dimensions one million times smaller than one centimeter ) ) ) [field_allegato_news] => Array ( ) [field_categorie_news] => Array ( [und] => Array ( [0] => Array ( [tid] => 2296 ) ) ) [field_pub_date] => Array ( [und] => Array ( [0] => Array ( [value] => 2024-03-11T00:00:00 [value2] => 2025-03-11T00:00:00 [timezone] => Europe/Paris [timezone_db] => Europe/Paris [date_type] => date ) ) ) [field_layout_news] => Array ( [und] => Array ( [0] => Array ( [value] => single ) ) ) [field_testo_opzionale_news] => Array ( ) [field_url_en_page] => Array ( ) [field_url_en_page_label] => Array ( ) [path] => Array ( [pathauto] => 1 ) [name] => francesca.forzan [picture] => 0 [data] => b:0; [num_revisions] => 1 [current_revision_id] => 451913 [is_current] => 1 [is_pending] => [revision_moderation] => [entity_view_prepared] => 1 ) [#items] => Array ( [0] => Array ( [value] => [format] => [safe_value] => ) ) [#formatter] => text_default [0] => Array ( [#markup] => ) ) [body] => Array ( [#theme] => field [#weight] => 0 [#title] => Body [#access] => 1 [#label_display] => hidden [#view_mode] => teaser [#language] => und [#field_name] => body [#field_type] => text_with_summary [#field_translatable] => 0 [#entity_type] => node [#bundle] => box_lancio_news [#object] => stdClass Object ( [vid] => 451913 [uid] => 2032 [title] => Measuring Entropy Production Rates. A Unipd Study [log] => [status] => 1 [comment] => 0 [promote] => 1 [sticky] => 0 [nid] => 108434 [type] => box_lancio_news [language] => it [created] => 1710146804 [changed] => 1710146804 [tnid] => 0 [translate] => 0 [revision_timestamp] => 1710146804 [revision_uid] => 2032 [body] => Array ( [und] => Array ( [0] => Array ( [value] =>

Researchers from the universities of Barcelona and Padua have developed a revolutionary methodology for measuring entropy production on dimensions one million times smaller than one centimeter. With affiliations from Universität Göttingen and Universidad Complutense, the Variance sum rule for entropy production study was published in the international peer-reviewed journal Science.

Despite many efforts, measuring entropy production at the nanoscale remains challenging. This study links entropy production to the flow of heat across the surface of the red blood cells that dissipates energy in the diluted fluid. Using precise calorimetry measurements, the result obtained is a million billion smaller than one calorie per second - a plate of pasta is equivalent to around 250 calories.

Operationally, the research teams detected heat flow resulting from active metabolic forces within red blood cells by observing the emerging flickering on their cell membrane. This flickering is the result of the incessant movement of molecular motors, the molecules that consume sugar to restructure cells.

"Heat is a symptom of cell health, and this finding could open up new ways to determine tissue health," explains lead researcher Professor Felix Ritort, Institute of Nanoscience and Nanotechnology, University of Barcelona. He adds, "Characterizing the entropy production in living systems is crucial for understanding the efficiency of energy conversion processes

[summary] => [format] => 2 [safe_value] =>

Researchers from the universities of Barcelona and Padua have developed a revolutionary methodology for measuring entropy production on dimensions one million times smaller than one centimeter. With affiliations from Universität Göttingen and Universidad Complutense, the Variance sum rule for entropy production study was published in the international peer-reviewed journal Science.

Despite many efforts, measuring entropy production at the nanoscale remains challenging. This study links entropy production to the flow of heat across the surface of the red blood cells that dissipates energy in the diluted fluid. Using precise calorimetry measurements, the result obtained is a million billion smaller than one calorie per second - a plate of pasta is equivalent to around 250 calories.

Operationally, the research teams detected heat flow resulting from active metabolic forces within red blood cells by observing the emerging flickering on their cell membrane. This flickering is the result of the incessant movement of molecular motors, the molecules that consume sugar to restructure cells.

"Heat is a symptom of cell health, and this finding could open up new ways to determine tissue health," explains lead researcher Professor Felix Ritort, Institute of Nanoscience and Nanotechnology, University of Barcelona. He adds, "Characterizing the entropy production in living systems is crucial for understanding the efficiency of energy conversion processes

[safe_summary] => ) ) ) [field_date_box_lancio_news] => Array ( [und] => Array ( [0] => Array ( [value] => 2024-03-11T00:00:00 [timezone] => Europe/Paris [timezone_db] => Europe/Paris [date_type] => date ) ) ) [field_etichetta_box_lancio_news] => Array ( ) [field_img_box_lancio_news] => Array ( [und] => Array ( [0] => Array ( [fid] => 128175 [uid] => 2032 [filename] => Immagine generata dall'intelligenza artificiale con l'evocazione di un globulo rosso che dissipa calore nell'ambiente.jpg [uri] => public://Immagine generata dall'intelligenza artificiale con l'evocazione di un globulo rosso che dissipa calore nell'ambiente_0.jpg [filemime] => image/jpeg [filesize] => 34606 [status] => 1 [timestamp] => 1710146804 [type] => image [field_file_image_alt_text] => Array ( ) [field_file_image_title_text] => Array ( ) [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2048 ) ) ) [metadata] => Array ( [height] => 227 [width] => 677 ) [height] => 227 [width] => 677 [alt] => globul [title] => ) ) ) [field_link_alla_news] => Array ( ) [field_link_esterno_news] => Array ( [und] => Array ( [0] => Array ( [value] => [format] => [safe_value] => ) ) ) [field_pagina_associata] => Array ( ) [field_link_etichetta] => Array ( ) [field_abstract_news] => Array ( [und] => Array ( [0] => Array ( [value] => Researchers from the universities of Barcelona and Padua have developed a revolutionary methodology for measuring entropy production on dimensions one million times smaller than one centimeter [format] => [safe_value] => Researchers from the universities of Barcelona and Padua have developed a revolutionary methodology for measuring entropy production on dimensions one million times smaller than one centimeter ) ) ) [field_allegato_news] => Array ( ) [field_categorie_news] => Array ( [und] => Array ( [0] => Array ( [tid] => 2296 ) ) ) [field_pub_date] => Array ( [und] => Array ( [0] => Array ( [value] => 2024-03-11T00:00:00 [value2] => 2025-03-11T00:00:00 [timezone] => Europe/Paris [timezone_db] => Europe/Paris [date_type] => date ) ) ) [field_layout_news] => Array ( [und] => Array ( [0] => Array ( [value] => single ) ) ) [field_testo_opzionale_news] => Array ( ) [field_url_en_page] => Array ( ) [field_url_en_page_label] => Array ( ) [path] => Array ( [pathauto] => 1 ) [name] => francesca.forzan [picture] => 0 [data] => b:0; [num_revisions] => 1 [current_revision_id] => 451913 [is_current] => 1 [is_pending] => [revision_moderation] => [entity_view_prepared] => 1 ) [#items] => Array ( [0] => Array ( [value] =>

Researchers from the universities of Barcelona and Padua have developed a revolutionary methodology for measuring entropy production on dimensions one million times smaller than one centimeter. With affiliations from Universität Göttingen and Universidad Complutense, the Variance sum rule for entropy production study was published in the international peer-reviewed journal Science.

Despite many efforts, measuring entropy production at the nanoscale remains challenging. This study links entropy production to the flow of heat across the surface of the red blood cells that dissipates energy in the diluted fluid. Using precise calorimetry measurements, the result obtained is a million billion smaller than one calorie per second - a plate of pasta is equivalent to around 250 calories.

Operationally, the research teams detected heat flow resulting from active metabolic forces within red blood cells by observing the emerging flickering on their cell membrane. This flickering is the result of the incessant movement of molecular motors, the molecules that consume sugar to restructure cells.

"Heat is a symptom of cell health, and this finding could open up new ways to determine tissue health," explains lead researcher Professor Felix Ritort, Institute of Nanoscience and Nanotechnology, University of Barcelona. He adds, "Characterizing the entropy production in living systems is crucial for understanding the efficiency of energy conversion processes

[summary] => [format] => 2 [safe_value] =>

Researchers from the universities of Barcelona and Padua have developed a revolutionary methodology for measuring entropy production on dimensions one million times smaller than one centimeter. With affiliations from Universität Göttingen and Universidad Complutense, the Variance sum rule for entropy production study was published in the international peer-reviewed journal Science.

Despite many efforts, measuring entropy production at the nanoscale remains challenging. This study links entropy production to the flow of heat across the surface of the red blood cells that dissipates energy in the diluted fluid. Using precise calorimetry measurements, the result obtained is a million billion smaller than one calorie per second - a plate of pasta is equivalent to around 250 calories.

Operationally, the research teams detected heat flow resulting from active metabolic forces within red blood cells by observing the emerging flickering on their cell membrane. This flickering is the result of the incessant movement of molecular motors, the molecules that consume sugar to restructure cells.

"Heat is a symptom of cell health, and this finding could open up new ways to determine tissue health," explains lead researcher Professor Felix Ritort, Institute of Nanoscience and Nanotechnology, University of Barcelona. He adds, "Characterizing the entropy production in living systems is crucial for understanding the efficiency of energy conversion processes

[safe_summary] => ) ) [#formatter] => text_summary_or_trimmed [0] => Array ( [#markup] =>

Researchers from the universities of Barcelona and Padua have developed a revolutionary methodology for measuring entropy production on dimensions one million times smaller than one centimeter. With affiliations from Universität Göttingen and Universidad Complutense, the Variance sum rule for entropy production study was published in the international peer-reviewed journal Science.

) ) [field_img_box_lancio_news] => Array ( [#theme] => field [#weight] => 0 [#title] => Immagine [#access] => 1 [#label_display] => above [#view_mode] => teaser [#language] => und [#field_name] => field_img_box_lancio_news [#field_type] => image [#field_translatable] => 0 [#entity_type] => node [#bundle] => box_lancio_news [#object] => stdClass Object ( [vid] => 451913 [uid] => 2032 [title] => Measuring Entropy Production Rates. A Unipd Study [log] => [status] => 1 [comment] => 0 [promote] => 1 [sticky] => 0 [nid] => 108434 [type] => box_lancio_news [language] => it [created] => 1710146804 [changed] => 1710146804 [tnid] => 0 [translate] => 0 [revision_timestamp] => 1710146804 [revision_uid] => 2032 [body] => Array ( [und] => Array ( [0] => Array ( [value] =>

Researchers from the universities of Barcelona and Padua have developed a revolutionary methodology for measuring entropy production on dimensions one million times smaller than one centimeter. With affiliations from Universität Göttingen and Universidad Complutense, the Variance sum rule for entropy production study was published in the international peer-reviewed journal Science.

Despite many efforts, measuring entropy production at the nanoscale remains challenging. This study links entropy production to the flow of heat across the surface of the red blood cells that dissipates energy in the diluted fluid. Using precise calorimetry measurements, the result obtained is a million billion smaller than one calorie per second - a plate of pasta is equivalent to around 250 calories.

Operationally, the research teams detected heat flow resulting from active metabolic forces within red blood cells by observing the emerging flickering on their cell membrane. This flickering is the result of the incessant movement of molecular motors, the molecules that consume sugar to restructure cells.

"Heat is a symptom of cell health, and this finding could open up new ways to determine tissue health," explains lead researcher Professor Felix Ritort, Institute of Nanoscience and Nanotechnology, University of Barcelona. He adds, "Characterizing the entropy production in living systems is crucial for understanding the efficiency of energy conversion processes

[summary] => [format] => 2 [safe_value] =>

Researchers from the universities of Barcelona and Padua have developed a revolutionary methodology for measuring entropy production on dimensions one million times smaller than one centimeter. With affiliations from Universität Göttingen and Universidad Complutense, the Variance sum rule for entropy production study was published in the international peer-reviewed journal Science.

Despite many efforts, measuring entropy production at the nanoscale remains challenging. This study links entropy production to the flow of heat across the surface of the red blood cells that dissipates energy in the diluted fluid. Using precise calorimetry measurements, the result obtained is a million billion smaller than one calorie per second - a plate of pasta is equivalent to around 250 calories.

Operationally, the research teams detected heat flow resulting from active metabolic forces within red blood cells by observing the emerging flickering on their cell membrane. This flickering is the result of the incessant movement of molecular motors, the molecules that consume sugar to restructure cells.

"Heat is a symptom of cell health, and this finding could open up new ways to determine tissue health," explains lead researcher Professor Felix Ritort, Institute of Nanoscience and Nanotechnology, University of Barcelona. He adds, "Characterizing the entropy production in living systems is crucial for understanding the efficiency of energy conversion processes

[safe_summary] => ) ) ) [field_date_box_lancio_news] => Array ( [und] => Array ( [0] => Array ( [value] => 2024-03-11T00:00:00 [timezone] => Europe/Paris [timezone_db] => Europe/Paris [date_type] => date ) ) ) [field_etichetta_box_lancio_news] => Array ( ) [field_img_box_lancio_news] => Array ( [und] => Array ( [0] => Array ( [fid] => 128175 [uid] => 2032 [filename] => Immagine generata dall'intelligenza artificiale con l'evocazione di un globulo rosso che dissipa calore nell'ambiente.jpg [uri] => public://Immagine generata dall'intelligenza artificiale con l'evocazione di un globulo rosso che dissipa calore nell'ambiente_0.jpg [filemime] => image/jpeg [filesize] => 34606 [status] => 1 [timestamp] => 1710146804 [type] => image [field_file_image_alt_text] => Array ( ) [field_file_image_title_text] => Array ( ) [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2048 ) ) ) [metadata] => Array ( [height] => 227 [width] => 677 ) [height] => 227 [width] => 677 [alt] => globul [title] => ) ) ) [field_link_alla_news] => Array ( ) [field_link_esterno_news] => Array ( [und] => Array ( [0] => Array ( [value] => [format] => [safe_value] => ) ) ) [field_pagina_associata] => Array ( ) [field_link_etichetta] => Array ( ) [field_abstract_news] => Array ( [und] => Array ( [0] => Array ( [value] => Researchers from the universities of Barcelona and Padua have developed a revolutionary methodology for measuring entropy production on dimensions one million times smaller than one centimeter [format] => [safe_value] => Researchers from the universities of Barcelona and Padua have developed a revolutionary methodology for measuring entropy production on dimensions one million times smaller than one centimeter ) ) ) [field_allegato_news] => Array ( ) [field_categorie_news] => Array ( [und] => Array ( [0] => Array ( [tid] => 2296 ) ) ) [field_pub_date] => Array ( [und] => Array ( [0] => Array ( [value] => 2024-03-11T00:00:00 [value2] => 2025-03-11T00:00:00 [timezone] => Europe/Paris [timezone_db] => Europe/Paris [date_type] => date ) ) ) [field_layout_news] => Array ( [und] => Array ( [0] => Array ( [value] => single ) ) ) [field_testo_opzionale_news] => Array ( ) [field_url_en_page] => Array ( ) [field_url_en_page_label] => Array ( ) [path] => Array ( [pathauto] => 1 ) [name] => francesca.forzan [picture] => 0 [data] => b:0; [num_revisions] => 1 [current_revision_id] => 451913 [is_current] => 1 [is_pending] => [revision_moderation] => [entity_view_prepared] => 1 ) [#items] => Array ( [0] => Array ( [fid] => 128175 [uid] => 2032 [filename] => Immagine generata dall'intelligenza artificiale con l'evocazione di un globulo rosso che dissipa calore nell'ambiente.jpg [uri] => public://Immagine generata dall'intelligenza artificiale con l'evocazione di un globulo rosso che dissipa calore nell'ambiente_0.jpg [filemime] => image/jpeg [filesize] => 34606 [status] => 1 [timestamp] => 1710146804 [type] => image [field_file_image_alt_text] => Array ( ) [field_file_image_title_text] => Array ( ) [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2048 ) ) ) [metadata] => Array ( [height] => 227 [width] => 677 ) [height] => 227 [width] => 677 [alt] => globul [title] => ) ) [#formatter] => image [0] => Array ( [#theme] => image_formatter [#item] => Array ( [fid] => 128175 [uid] => 2032 [filename] => Immagine generata dall'intelligenza artificiale con l'evocazione di un globulo rosso che dissipa calore nell'ambiente.jpg [uri] => public://Immagine generata dall'intelligenza artificiale con l'evocazione di un globulo rosso che dissipa calore nell'ambiente_0.jpg [filemime] => image/jpeg [filesize] => 34606 [status] => 1 [timestamp] => 1710146804 [type] => image [field_file_image_alt_text] => Array ( ) [field_file_image_title_text] => Array ( ) [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2048 ) ) ) [metadata] => Array ( [height] => 227 [width] => 677 ) [height] => 227 [width] => 677 [alt] => globul [title] => ) [#image_style] => [#path] => ) ) [field_abstract_news] => Array ( [#theme] => field [#weight] => 0 [#title] => Abstract [#access] => 1 [#label_display] => above [#view_mode] => teaser [#language] => und [#field_name] => field_abstract_news [#field_type] => text_long [#field_translatable] => 0 [#entity_type] => node [#bundle] => box_lancio_news [#object] => stdClass Object ( [vid] => 451913 [uid] => 2032 [title] => Measuring Entropy Production Rates. A Unipd Study [log] => [status] => 1 [comment] => 0 [promote] => 1 [sticky] => 0 [nid] => 108434 [type] => box_lancio_news [language] => it [created] => 1710146804 [changed] => 1710146804 [tnid] => 0 [translate] => 0 [revision_timestamp] => 1710146804 [revision_uid] => 2032 [body] => Array ( [und] => Array ( [0] => Array ( [value] =>

Researchers from the universities of Barcelona and Padua have developed a revolutionary methodology for measuring entropy production on dimensions one million times smaller than one centimeter. With affiliations from Universität Göttingen and Universidad Complutense, the Variance sum rule for entropy production study was published in the international peer-reviewed journal Science.

Despite many efforts, measuring entropy production at the nanoscale remains challenging. This study links entropy production to the flow of heat across the surface of the red blood cells that dissipates energy in the diluted fluid. Using precise calorimetry measurements, the result obtained is a million billion smaller than one calorie per second - a plate of pasta is equivalent to around 250 calories.

Operationally, the research teams detected heat flow resulting from active metabolic forces within red blood cells by observing the emerging flickering on their cell membrane. This flickering is the result of the incessant movement of molecular motors, the molecules that consume sugar to restructure cells.

"Heat is a symptom of cell health, and this finding could open up new ways to determine tissue health," explains lead researcher Professor Felix Ritort, Institute of Nanoscience and Nanotechnology, University of Barcelona. He adds, "Characterizing the entropy production in living systems is crucial for understanding the efficiency of energy conversion processes

[summary] => [format] => 2 [safe_value] =>

Researchers from the universities of Barcelona and Padua have developed a revolutionary methodology for measuring entropy production on dimensions one million times smaller than one centimeter. With affiliations from Universität Göttingen and Universidad Complutense, the Variance sum rule for entropy production study was published in the international peer-reviewed journal Science.

Despite many efforts, measuring entropy production at the nanoscale remains challenging. This study links entropy production to the flow of heat across the surface of the red blood cells that dissipates energy in the diluted fluid. Using precise calorimetry measurements, the result obtained is a million billion smaller than one calorie per second - a plate of pasta is equivalent to around 250 calories.

Operationally, the research teams detected heat flow resulting from active metabolic forces within red blood cells by observing the emerging flickering on their cell membrane. This flickering is the result of the incessant movement of molecular motors, the molecules that consume sugar to restructure cells.

"Heat is a symptom of cell health, and this finding could open up new ways to determine tissue health," explains lead researcher Professor Felix Ritort, Institute of Nanoscience and Nanotechnology, University of Barcelona. He adds, "Characterizing the entropy production in living systems is crucial for understanding the efficiency of energy conversion processes

[safe_summary] => ) ) ) [field_date_box_lancio_news] => Array ( [und] => Array ( [0] => Array ( [value] => 2024-03-11T00:00:00 [timezone] => Europe/Paris [timezone_db] => Europe/Paris [date_type] => date ) ) ) [field_etichetta_box_lancio_news] => Array ( ) [field_img_box_lancio_news] => Array ( [und] => Array ( [0] => Array ( [fid] => 128175 [uid] => 2032 [filename] => Immagine generata dall'intelligenza artificiale con l'evocazione di un globulo rosso che dissipa calore nell'ambiente.jpg [uri] => public://Immagine generata dall'intelligenza artificiale con l'evocazione di un globulo rosso che dissipa calore nell'ambiente_0.jpg [filemime] => image/jpeg [filesize] => 34606 [status] => 1 [timestamp] => 1710146804 [type] => image [field_file_image_alt_text] => Array ( ) [field_file_image_title_text] => Array ( ) [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2048 ) ) ) [metadata] => Array ( [height] => 227 [width] => 677 ) [height] => 227 [width] => 677 [alt] => globul [title] => ) ) ) [field_link_alla_news] => Array ( ) [field_link_esterno_news] => Array ( [und] => Array ( [0] => Array ( [value] => [format] => [safe_value] => ) ) ) [field_pagina_associata] => Array ( ) [field_link_etichetta] => Array ( ) [field_abstract_news] => Array ( [und] => Array ( [0] => Array ( [value] => Researchers from the universities of Barcelona and Padua have developed a revolutionary methodology for measuring entropy production on dimensions one million times smaller than one centimeter [format] => [safe_value] => Researchers from the universities of Barcelona and Padua have developed a revolutionary methodology for measuring entropy production on dimensions one million times smaller than one centimeter ) ) ) [field_allegato_news] => Array ( ) [field_categorie_news] => Array ( [und] => Array ( [0] => Array ( [tid] => 2296 ) ) ) [field_pub_date] => Array ( [und] => Array ( [0] => Array ( [value] => 2024-03-11T00:00:00 [value2] => 2025-03-11T00:00:00 [timezone] => Europe/Paris [timezone_db] => Europe/Paris [date_type] => date ) ) ) [field_layout_news] => Array ( [und] => Array ( [0] => Array ( [value] => single ) ) ) [field_testo_opzionale_news] => Array ( ) [field_url_en_page] => Array ( ) [field_url_en_page_label] => Array ( ) [path] => Array ( [pathauto] => 1 ) [name] => francesca.forzan [picture] => 0 [data] => b:0; [num_revisions] => 1 [current_revision_id] => 451913 [is_current] => 1 [is_pending] => [revision_moderation] => [entity_view_prepared] => 1 ) [#items] => Array ( [0] => Array ( [value] => Researchers from the universities of Barcelona and Padua have developed a revolutionary methodology for measuring entropy production on dimensions one million times smaller than one centimeter [format] => [safe_value] => Researchers from the universities of Barcelona and Padua have developed a revolutionary methodology for measuring entropy production on dimensions one million times smaller than one centimeter ) ) [#formatter] => text_default [0] => Array ( [#markup] => Researchers from the universities of Barcelona and Padua have developed a revolutionary methodology for measuring entropy production on dimensions one million times smaller than one centimeter ) ) [links] => Array ( [#theme] => links__node [#pre_render] => Array ( [0] => drupal_pre_render_links ) [#attributes] => Array ( [class] => Array ( [0] => links [1] => inline ) ) [node] => Array ( [#theme] => links__node__node [#links] => Array ( [node-readmore] => Array ( [title] => Read more about Measuring Entropy Production Rates. A Unipd Study [href] => node/108434 [html] => 1 [attributes] => Array ( [rel] => tag [title] => Measuring Entropy Production Rates. A Unipd Study ) ) ) [#attributes] => Array ( [class] => Array ( [0] => links [1] => inline ) ) ) ) [field_date_box_lancio_news] => Array ( [#theme] => field [#weight] => 1 [#title] => Data [#access] => 1 [#label_display] => above [#view_mode] => teaser [#language] => und [#field_name] => field_date_box_lancio_news [#field_type] => date [#field_translatable] => 0 [#entity_type] => node [#bundle] => box_lancio_news [#object] => stdClass Object ( [vid] => 451913 [uid] => 2032 [title] => Measuring Entropy Production Rates. A Unipd Study [log] => [status] => 1 [comment] => 0 [promote] => 1 [sticky] => 0 [nid] => 108434 [type] => box_lancio_news [language] => it [created] => 1710146804 [changed] => 1710146804 [tnid] => 0 [translate] => 0 [revision_timestamp] => 1710146804 [revision_uid] => 2032 [body] => Array ( [und] => Array ( [0] => Array ( [value] =>

Researchers from the universities of Barcelona and Padua have developed a revolutionary methodology for measuring entropy production on dimensions one million times smaller than one centimeter. With affiliations from Universität Göttingen and Universidad Complutense, the Variance sum rule for entropy production study was published in the international peer-reviewed journal Science.

Despite many efforts, measuring entropy production at the nanoscale remains challenging. This study links entropy production to the flow of heat across the surface of the red blood cells that dissipates energy in the diluted fluid. Using precise calorimetry measurements, the result obtained is a million billion smaller than one calorie per second - a plate of pasta is equivalent to around 250 calories.

Operationally, the research teams detected heat flow resulting from active metabolic forces within red blood cells by observing the emerging flickering on their cell membrane. This flickering is the result of the incessant movement of molecular motors, the molecules that consume sugar to restructure cells.

"Heat is a symptom of cell health, and this finding could open up new ways to determine tissue health," explains lead researcher Professor Felix Ritort, Institute of Nanoscience and Nanotechnology, University of Barcelona. He adds, "Characterizing the entropy production in living systems is crucial for understanding the efficiency of energy conversion processes

[summary] => [format] => 2 [safe_value] =>

Researchers from the universities of Barcelona and Padua have developed a revolutionary methodology for measuring entropy production on dimensions one million times smaller than one centimeter. With affiliations from Universität Göttingen and Universidad Complutense, the Variance sum rule for entropy production study was published in the international peer-reviewed journal Science.

Despite many efforts, measuring entropy production at the nanoscale remains challenging. This study links entropy production to the flow of heat across the surface of the red blood cells that dissipates energy in the diluted fluid. Using precise calorimetry measurements, the result obtained is a million billion smaller than one calorie per second - a plate of pasta is equivalent to around 250 calories.

Operationally, the research teams detected heat flow resulting from active metabolic forces within red blood cells by observing the emerging flickering on their cell membrane. This flickering is the result of the incessant movement of molecular motors, the molecules that consume sugar to restructure cells.

"Heat is a symptom of cell health, and this finding could open up new ways to determine tissue health," explains lead researcher Professor Felix Ritort, Institute of Nanoscience and Nanotechnology, University of Barcelona. He adds, "Characterizing the entropy production in living systems is crucial for understanding the efficiency of energy conversion processes

[safe_summary] => ) ) ) [field_date_box_lancio_news] => Array ( [und] => Array ( [0] => Array ( [value] => 2024-03-11T00:00:00 [timezone] => Europe/Paris [timezone_db] => Europe/Paris [date_type] => date ) ) ) [field_etichetta_box_lancio_news] => Array ( ) [field_img_box_lancio_news] => Array ( [und] => Array ( [0] => Array ( [fid] => 128175 [uid] => 2032 [filename] => Immagine generata dall'intelligenza artificiale con l'evocazione di un globulo rosso che dissipa calore nell'ambiente.jpg [uri] => public://Immagine generata dall'intelligenza artificiale con l'evocazione di un globulo rosso che dissipa calore nell'ambiente_0.jpg [filemime] => image/jpeg [filesize] => 34606 [status] => 1 [timestamp] => 1710146804 [type] => image [field_file_image_alt_text] => Array ( ) [field_file_image_title_text] => Array ( ) [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2048 ) ) ) [metadata] => Array ( [height] => 227 [width] => 677 ) [height] => 227 [width] => 677 [alt] => globul [title] => ) ) ) [field_link_alla_news] => Array ( ) [field_link_esterno_news] => Array ( [und] => Array ( [0] => Array ( [value] => [format] => [safe_value] => ) ) ) [field_pagina_associata] => Array ( ) [field_link_etichetta] => Array ( ) [field_abstract_news] => Array ( [und] => Array ( [0] => Array ( [value] => Researchers from the universities of Barcelona and Padua have developed a revolutionary methodology for measuring entropy production on dimensions one million times smaller than one centimeter [format] => [safe_value] => Researchers from the universities of Barcelona and Padua have developed a revolutionary methodology for measuring entropy production on dimensions one million times smaller than one centimeter ) ) ) [field_allegato_news] => Array ( ) [field_categorie_news] => Array ( [und] => Array ( [0] => Array ( [tid] => 2296 ) ) ) [field_pub_date] => Array ( [und] => Array ( [0] => Array ( [value] => 2024-03-11T00:00:00 [value2] => 2025-03-11T00:00:00 [timezone] => Europe/Paris [timezone_db] => Europe/Paris [date_type] => date ) ) ) [field_layout_news] => Array ( [und] => Array ( [0] => Array ( [value] => single ) ) ) [field_testo_opzionale_news] => Array ( ) [field_url_en_page] => Array ( ) [field_url_en_page_label] => Array ( ) [path] => Array ( [pathauto] => 1 ) [name] => francesca.forzan [picture] => 0 [data] => b:0; [num_revisions] => 1 [current_revision_id] => 451913 [is_current] => 1 [is_pending] => [revision_moderation] => [entity_view_prepared] => 1 ) [#items] => Array ( [0] => Array ( [value] => 2024-03-11T00:00:00 [timezone] => Europe/Paris [timezone_db] => Europe/Paris [date_type] => date ) ) [#formatter] => date_default [0] => Array ( [#markup] => Lun, 11/03/2024 ) ) )

LIVERAIM - Developing a European Screening Platform for Liver Disease

Array ( [field_link_esterno_news] => Array ( [#theme] => field [#weight] => -1 [#title] => Link esterno news [#access] => 1 [#label_display] => above [#view_mode] => teaser [#language] => und [#field_name] => field_link_esterno_news [#field_type] => text_long [#field_translatable] => 0 [#entity_type] => node [#bundle] => box_lancio_news [#object] => stdClass Object ( [vid] => 451912 [uid] => 2032 [title] => LIVERAIM - Developing a European Screening Platform for Liver Disease [log] => [status] => 1 [comment] => 0 [promote] => 1 [sticky] => 0 [nid] => 108433 [type] => box_lancio_news [language] => it [created] => 1710146499 [changed] => 1710146499 [tnid] => 0 [translate] => 0 [revision_timestamp] => 1710146499 [revision_uid] => 2032 [body] => Array ( [und] => Array ( [0] => Array ( [value] =>

LIVERAIM, a European research project that includes researchers from the University of Padua and its Teaching Hospital aims to improve the life and health of those suffering from liver diseases thanks to the start of the largest study carried out in this field.

Prof Paolo Angeli of the Department of Medicine at the University of Padua and Chief of the Unit of Internal Medicine and Hepatology at the University Teaching Hospital of Padua explains, “Liver cirrhosis and liver cancer are common and responsible for high morbidity, impaired quality of life, major costs for healthcare systems, and causing 300K deaths per year in Europe. Liver disease often progresses asymptomatically, until serious symptoms and complications occur. Unfortunately, at this advanced stage, treatment options are limited and liver transplantation is often the option. However, if detected early during the fibrosis stage, its progression can be prevented through effective interventions.”

Prof Salvatore Silvio Piano of the Department of Medicine at the University of Padua and local coordinator of the project comments, “The absence of an effective screening program represents a significant barrier to the early identification of these pathologies. While we have been successfully conducting liver disease screening in the Veneto region through the non-invasive test called Fibroscan, this method is only available at special clinics and centers.  If we want to promote a large-scale population screening, we must include general practitioners by providing them with tools such as a blood test to accurately identify individuals at risk of liver disease who may require in depth evaluations.”

With total funding of over 20M euros as part of the Innovation Health Initiative, the Joint Undertaking European LIVERAIM Project will see approximately 1,800,000 euros allocated to the University of Padua and its University Hospital.

LIVERAIM will design and validate a screening platform with biomarkers for population screening to use across Europe. The objective is to identify liver disease early and apply personalized therapeutic interventions.

[summary] => [format] => 2 [safe_value] =>

LIVERAIM, a European research project that includes researchers from the University of Padua and its Teaching Hospital aims to improve the life and health of those suffering from liver diseases thanks to the start of the largest study carried out in this field.

Prof Paolo Angeli of the Department of Medicine at the University of Padua and Chief of the Unit of Internal Medicine and Hepatology at the University Teaching Hospital of Padua explains, “Liver cirrhosis and liver cancer are common and responsible for high morbidity, impaired quality of life, major costs for healthcare systems, and causing 300K deaths per year in Europe. Liver disease often progresses asymptomatically, until serious symptoms and complications occur. Unfortunately, at this advanced stage, treatment options are limited and liver transplantation is often the option. However, if detected early during the fibrosis stage, its progression can be prevented through effective interventions.”

Prof Salvatore Silvio Piano of the Department of Medicine at the University of Padua and local coordinator of the project comments, “The absence of an effective screening program represents a significant barrier to the early identification of these pathologies. While we have been successfully conducting liver disease screening in the Veneto region through the non-invasive test called Fibroscan, this method is only available at special clinics and centers.  If we want to promote a large-scale population screening, we must include general practitioners by providing them with tools such as a blood test to accurately identify individuals at risk of liver disease who may require in depth evaluations.”

With total funding of over 20M euros as part of the Innovation Health Initiative, the Joint Undertaking European LIVERAIM Project will see approximately 1,800,000 euros allocated to the University of Padua and its University Hospital.

LIVERAIM will design and validate a screening platform with biomarkers for population screening to use across Europe. The objective is to identify liver disease early and apply personalized therapeutic interventions.

[safe_summary] => ) ) ) [field_date_box_lancio_news] => Array ( [und] => Array ( [0] => Array ( [value] => 2024-03-11T00:00:00 [timezone] => Europe/Paris [timezone_db] => Europe/Paris [date_type] => date ) ) ) [field_etichetta_box_lancio_news] => Array ( ) [field_img_box_lancio_news] => Array ( [und] => Array ( [0] => Array ( [fid] => 128174 [uid] => 2032 [filename] => n_fegato_medico.jpg [uri] => public://n_fegato_medico_0.jpg [filemime] => image/jpeg [filesize] => 19361 [status] => 1 [timestamp] => 1710146499 [type] => image [field_file_image_alt_text] => Array ( ) [field_file_image_title_text] => Array ( ) [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2048 ) ) ) [metadata] => Array ( [height] => 227 [width] => 677 ) [height] => 227 [width] => 677 [alt] => liver [title] => ) ) ) [field_link_alla_news] => Array ( ) [field_link_esterno_news] => Array ( [und] => Array ( [0] => Array ( [value] => [format] => [safe_value] => ) ) ) [field_pagina_associata] => Array ( ) [field_link_etichetta] => Array ( ) [field_abstract_news] => Array ( [und] => Array ( [0] => Array ( [value] => The Unipd research for early detection of liver disease will be funded with approximately 1,800,000 euros [format] => [safe_value] => The Unipd research for early detection of liver disease will be funded with approximately 1,800,000 euros ) ) ) [field_allegato_news] => Array ( ) [field_categorie_news] => Array ( [und] => Array ( [0] => Array ( [tid] => 2261 ) [1] => Array ( [tid] => 2296 ) ) ) [field_pub_date] => Array ( [und] => Array ( [0] => Array ( [value] => 2024-03-11T00:00:00 [value2] => 2025-03-11T00:00:00 [timezone] => Europe/Paris [timezone_db] => Europe/Paris [date_type] => date ) ) ) [field_layout_news] => Array ( [und] => Array ( [0] => Array ( [value] => single ) ) ) [field_testo_opzionale_news] => Array ( ) [field_url_en_page] => Array ( ) [field_url_en_page_label] => Array ( ) [path] => Array ( [pathauto] => 1 ) [name] => francesca.forzan [picture] => 0 [data] => b:0; [num_revisions] => 1 [current_revision_id] => 451912 [is_current] => 1 [is_pending] => [revision_moderation] => [entity_view_prepared] => 1 ) [#items] => Array ( [0] => Array ( [value] => [format] => [safe_value] => ) ) [#formatter] => text_default [0] => Array ( [#markup] => ) ) [body] => Array ( [#theme] => field [#weight] => 0 [#title] => Body [#access] => 1 [#label_display] => hidden [#view_mode] => teaser [#language] => und [#field_name] => body [#field_type] => text_with_summary [#field_translatable] => 0 [#entity_type] => node [#bundle] => box_lancio_news [#object] => stdClass Object ( [vid] => 451912 [uid] => 2032 [title] => LIVERAIM - Developing a European Screening Platform for Liver Disease [log] => [status] => 1 [comment] => 0 [promote] => 1 [sticky] => 0 [nid] => 108433 [type] => box_lancio_news [language] => it [created] => 1710146499 [changed] => 1710146499 [tnid] => 0 [translate] => 0 [revision_timestamp] => 1710146499 [revision_uid] => 2032 [body] => Array ( [und] => Array ( [0] => Array ( [value] =>

LIVERAIM, a European research project that includes researchers from the University of Padua and its Teaching Hospital aims to improve the life and health of those suffering from liver diseases thanks to the start of the largest study carried out in this field.

Prof Paolo Angeli of the Department of Medicine at the University of Padua and Chief of the Unit of Internal Medicine and Hepatology at the University Teaching Hospital of Padua explains, “Liver cirrhosis and liver cancer are common and responsible for high morbidity, impaired quality of life, major costs for healthcare systems, and causing 300K deaths per year in Europe. Liver disease often progresses asymptomatically, until serious symptoms and complications occur. Unfortunately, at this advanced stage, treatment options are limited and liver transplantation is often the option. However, if detected early during the fibrosis stage, its progression can be prevented through effective interventions.”

Prof Salvatore Silvio Piano of the Department of Medicine at the University of Padua and local coordinator of the project comments, “The absence of an effective screening program represents a significant barrier to the early identification of these pathologies. While we have been successfully conducting liver disease screening in the Veneto region through the non-invasive test called Fibroscan, this method is only available at special clinics and centers.  If we want to promote a large-scale population screening, we must include general practitioners by providing them with tools such as a blood test to accurately identify individuals at risk of liver disease who may require in depth evaluations.”

With total funding of over 20M euros as part of the Innovation Health Initiative, the Joint Undertaking European LIVERAIM Project will see approximately 1,800,000 euros allocated to the University of Padua and its University Hospital.

LIVERAIM will design and validate a screening platform with biomarkers for population screening to use across Europe. The objective is to identify liver disease early and apply personalized therapeutic interventions.

[summary] => [format] => 2 [safe_value] =>

LIVERAIM, a European research project that includes researchers from the University of Padua and its Teaching Hospital aims to improve the life and health of those suffering from liver diseases thanks to the start of the largest study carried out in this field.

Prof Paolo Angeli of the Department of Medicine at the University of Padua and Chief of the Unit of Internal Medicine and Hepatology at the University Teaching Hospital of Padua explains, “Liver cirrhosis and liver cancer are common and responsible for high morbidity, impaired quality of life, major costs for healthcare systems, and causing 300K deaths per year in Europe. Liver disease often progresses asymptomatically, until serious symptoms and complications occur. Unfortunately, at this advanced stage, treatment options are limited and liver transplantation is often the option. However, if detected early during the fibrosis stage, its progression can be prevented through effective interventions.”

Prof Salvatore Silvio Piano of the Department of Medicine at the University of Padua and local coordinator of the project comments, “The absence of an effective screening program represents a significant barrier to the early identification of these pathologies. While we have been successfully conducting liver disease screening in the Veneto region through the non-invasive test called Fibroscan, this method is only available at special clinics and centers.  If we want to promote a large-scale population screening, we must include general practitioners by providing them with tools such as a blood test to accurately identify individuals at risk of liver disease who may require in depth evaluations.”

With total funding of over 20M euros as part of the Innovation Health Initiative, the Joint Undertaking European LIVERAIM Project will see approximately 1,800,000 euros allocated to the University of Padua and its University Hospital.

LIVERAIM will design and validate a screening platform with biomarkers for population screening to use across Europe. The objective is to identify liver disease early and apply personalized therapeutic interventions.

[safe_summary] => ) ) ) [field_date_box_lancio_news] => Array ( [und] => Array ( [0] => Array ( [value] => 2024-03-11T00:00:00 [timezone] => Europe/Paris [timezone_db] => Europe/Paris [date_type] => date ) ) ) [field_etichetta_box_lancio_news] => Array ( ) [field_img_box_lancio_news] => Array ( [und] => Array ( [0] => Array ( [fid] => 128174 [uid] => 2032 [filename] => n_fegato_medico.jpg [uri] => public://n_fegato_medico_0.jpg [filemime] => image/jpeg [filesize] => 19361 [status] => 1 [timestamp] => 1710146499 [type] => image [field_file_image_alt_text] => Array ( ) [field_file_image_title_text] => Array ( ) [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2048 ) ) ) [metadata] => Array ( [height] => 227 [width] => 677 ) [height] => 227 [width] => 677 [alt] => liver [title] => ) ) ) [field_link_alla_news] => Array ( ) [field_link_esterno_news] => Array ( [und] => Array ( [0] => Array ( [value] => [format] => [safe_value] => ) ) ) [field_pagina_associata] => Array ( ) [field_link_etichetta] => Array ( ) [field_abstract_news] => Array ( [und] => Array ( [0] => Array ( [value] => The Unipd research for early detection of liver disease will be funded with approximately 1,800,000 euros [format] => [safe_value] => The Unipd research for early detection of liver disease will be funded with approximately 1,800,000 euros ) ) ) [field_allegato_news] => Array ( ) [field_categorie_news] => Array ( [und] => Array ( [0] => Array ( [tid] => 2261 ) [1] => Array ( [tid] => 2296 ) ) ) [field_pub_date] => Array ( [und] => Array ( [0] => Array ( [value] => 2024-03-11T00:00:00 [value2] => 2025-03-11T00:00:00 [timezone] => Europe/Paris [timezone_db] => Europe/Paris [date_type] => date ) ) ) [field_layout_news] => Array ( [und] => Array ( [0] => Array ( [value] => single ) ) ) [field_testo_opzionale_news] => Array ( ) [field_url_en_page] => Array ( ) [field_url_en_page_label] => Array ( ) [path] => Array ( [pathauto] => 1 ) [name] => francesca.forzan [picture] => 0 [data] => b:0; [num_revisions] => 1 [current_revision_id] => 451912 [is_current] => 1 [is_pending] => [revision_moderation] => [entity_view_prepared] => 1 ) [#items] => Array ( [0] => Array ( [value] =>

LIVERAIM, a European research project that includes researchers from the University of Padua and its Teaching Hospital aims to improve the life and health of those suffering from liver diseases thanks to the start of the largest study carried out in this field.

Prof Paolo Angeli of the Department of Medicine at the University of Padua and Chief of the Unit of Internal Medicine and Hepatology at the University Teaching Hospital of Padua explains, “Liver cirrhosis and liver cancer are common and responsible for high morbidity, impaired quality of life, major costs for healthcare systems, and causing 300K deaths per year in Europe. Liver disease often progresses asymptomatically, until serious symptoms and complications occur. Unfortunately, at this advanced stage, treatment options are limited and liver transplantation is often the option. However, if detected early during the fibrosis stage, its progression can be prevented through effective interventions.”

Prof Salvatore Silvio Piano of the Department of Medicine at the University of Padua and local coordinator of the project comments, “The absence of an effective screening program represents a significant barrier to the early identification of these pathologies. While we have been successfully conducting liver disease screening in the Veneto region through the non-invasive test called Fibroscan, this method is only available at special clinics and centers.  If we want to promote a large-scale population screening, we must include general practitioners by providing them with tools such as a blood test to accurately identify individuals at risk of liver disease who may require in depth evaluations.”

With total funding of over 20M euros as part of the Innovation Health Initiative, the Joint Undertaking European LIVERAIM Project will see approximately 1,800,000 euros allocated to the University of Padua and its University Hospital.

LIVERAIM will design and validate a screening platform with biomarkers for population screening to use across Europe. The objective is to identify liver disease early and apply personalized therapeutic interventions.

[summary] => [format] => 2 [safe_value] =>

LIVERAIM, a European research project that includes researchers from the University of Padua and its Teaching Hospital aims to improve the life and health of those suffering from liver diseases thanks to the start of the largest study carried out in this field.

Prof Paolo Angeli of the Department of Medicine at the University of Padua and Chief of the Unit of Internal Medicine and Hepatology at the University Teaching Hospital of Padua explains, “Liver cirrhosis and liver cancer are common and responsible for high morbidity, impaired quality of life, major costs for healthcare systems, and causing 300K deaths per year in Europe. Liver disease often progresses asymptomatically, until serious symptoms and complications occur. Unfortunately, at this advanced stage, treatment options are limited and liver transplantation is often the option. However, if detected early during the fibrosis stage, its progression can be prevented through effective interventions.”

Prof Salvatore Silvio Piano of the Department of Medicine at the University of Padua and local coordinator of the project comments, “The absence of an effective screening program represents a significant barrier to the early identification of these pathologies. While we have been successfully conducting liver disease screening in the Veneto region through the non-invasive test called Fibroscan, this method is only available at special clinics and centers.  If we want to promote a large-scale population screening, we must include general practitioners by providing them with tools such as a blood test to accurately identify individuals at risk of liver disease who may require in depth evaluations.”

With total funding of over 20M euros as part of the Innovation Health Initiative, the Joint Undertaking European LIVERAIM Project will see approximately 1,800,000 euros allocated to the University of Padua and its University Hospital.

LIVERAIM will design and validate a screening platform with biomarkers for population screening to use across Europe. The objective is to identify liver disease early and apply personalized therapeutic interventions.

[safe_summary] => ) ) [#formatter] => text_summary_or_trimmed [0] => Array ( [#markup] =>

LIVERAIM, a European research project that includes researchers from the University of Padua and its Teaching Hospital aims to improve the life and health of those suffering from liver diseases thanks to the start of the largest study carried out in this field.

) ) [field_img_box_lancio_news] => Array ( [#theme] => field [#weight] => 0 [#title] => Immagine [#access] => 1 [#label_display] => above [#view_mode] => teaser [#language] => und [#field_name] => field_img_box_lancio_news [#field_type] => image [#field_translatable] => 0 [#entity_type] => node [#bundle] => box_lancio_news [#object] => stdClass Object ( [vid] => 451912 [uid] => 2032 [title] => LIVERAIM - Developing a European Screening Platform for Liver Disease [log] => [status] => 1 [comment] => 0 [promote] => 1 [sticky] => 0 [nid] => 108433 [type] => box_lancio_news [language] => it [created] => 1710146499 [changed] => 1710146499 [tnid] => 0 [translate] => 0 [revision_timestamp] => 1710146499 [revision_uid] => 2032 [body] => Array ( [und] => Array ( [0] => Array ( [value] =>

LIVERAIM, a European research project that includes researchers from the University of Padua and its Teaching Hospital aims to improve the life and health of those suffering from liver diseases thanks to the start of the largest study carried out in this field.

Prof Paolo Angeli of the Department of Medicine at the University of Padua and Chief of the Unit of Internal Medicine and Hepatology at the University Teaching Hospital of Padua explains, “Liver cirrhosis and liver cancer are common and responsible for high morbidity, impaired quality of life, major costs for healthcare systems, and causing 300K deaths per year in Europe. Liver disease often progresses asymptomatically, until serious symptoms and complications occur. Unfortunately, at this advanced stage, treatment options are limited and liver transplantation is often the option. However, if detected early during the fibrosis stage, its progression can be prevented through effective interventions.”

Prof Salvatore Silvio Piano of the Department of Medicine at the University of Padua and local coordinator of the project comments, “The absence of an effective screening program represents a significant barrier to the early identification of these pathologies. While we have been successfully conducting liver disease screening in the Veneto region through the non-invasive test called Fibroscan, this method is only available at special clinics and centers.  If we want to promote a large-scale population screening, we must include general practitioners by providing them with tools such as a blood test to accurately identify individuals at risk of liver disease who may require in depth evaluations.”

With total funding of over 20M euros as part of the Innovation Health Initiative, the Joint Undertaking European LIVERAIM Project will see approximately 1,800,000 euros allocated to the University of Padua and its University Hospital.

LIVERAIM will design and validate a screening platform with biomarkers for population screening to use across Europe. The objective is to identify liver disease early and apply personalized therapeutic interventions.

[summary] => [format] => 2 [safe_value] =>

LIVERAIM, a European research project that includes researchers from the University of Padua and its Teaching Hospital aims to improve the life and health of those suffering from liver diseases thanks to the start of the largest study carried out in this field.

Prof Paolo Angeli of the Department of Medicine at the University of Padua and Chief of the Unit of Internal Medicine and Hepatology at the University Teaching Hospital of Padua explains, “Liver cirrhosis and liver cancer are common and responsible for high morbidity, impaired quality of life, major costs for healthcare systems, and causing 300K deaths per year in Europe. Liver disease often progresses asymptomatically, until serious symptoms and complications occur. Unfortunately, at this advanced stage, treatment options are limited and liver transplantation is often the option. However, if detected early during the fibrosis stage, its progression can be prevented through effective interventions.”

Prof Salvatore Silvio Piano of the Department of Medicine at the University of Padua and local coordinator of the project comments, “The absence of an effective screening program represents a significant barrier to the early identification of these pathologies. While we have been successfully conducting liver disease screening in the Veneto region through the non-invasive test called Fibroscan, this method is only available at special clinics and centers.  If we want to promote a large-scale population screening, we must include general practitioners by providing them with tools such as a blood test to accurately identify individuals at risk of liver disease who may require in depth evaluations.”

With total funding of over 20M euros as part of the Innovation Health Initiative, the Joint Undertaking European LIVERAIM Project will see approximately 1,800,000 euros allocated to the University of Padua and its University Hospital.

LIVERAIM will design and validate a screening platform with biomarkers for population screening to use across Europe. The objective is to identify liver disease early and apply personalized therapeutic interventions.

[safe_summary] => ) ) ) [field_date_box_lancio_news] => Array ( [und] => Array ( [0] => Array ( [value] => 2024-03-11T00:00:00 [timezone] => Europe/Paris [timezone_db] => Europe/Paris [date_type] => date ) ) ) [field_etichetta_box_lancio_news] => Array ( ) [field_img_box_lancio_news] => Array ( [und] => Array ( [0] => Array ( [fid] => 128174 [uid] => 2032 [filename] => n_fegato_medico.jpg [uri] => public://n_fegato_medico_0.jpg [filemime] => image/jpeg [filesize] => 19361 [status] => 1 [timestamp] => 1710146499 [type] => image [field_file_image_alt_text] => Array ( ) [field_file_image_title_text] => Array ( ) [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2048 ) ) ) [metadata] => Array ( [height] => 227 [width] => 677 ) [height] => 227 [width] => 677 [alt] => liver [title] => ) ) ) [field_link_alla_news] => Array ( ) [field_link_esterno_news] => Array ( [und] => Array ( [0] => Array ( [value] => [format] => [safe_value] => ) ) ) [field_pagina_associata] => Array ( ) [field_link_etichetta] => Array ( ) [field_abstract_news] => Array ( [und] => Array ( [0] => Array ( [value] => The Unipd research for early detection of liver disease will be funded with approximately 1,800,000 euros [format] => [safe_value] => The Unipd research for early detection of liver disease will be funded with approximately 1,800,000 euros ) ) ) [field_allegato_news] => Array ( ) [field_categorie_news] => Array ( [und] => Array ( [0] => Array ( [tid] => 2261 ) [1] => Array ( [tid] => 2296 ) ) ) [field_pub_date] => Array ( [und] => Array ( [0] => Array ( [value] => 2024-03-11T00:00:00 [value2] => 2025-03-11T00:00:00 [timezone] => Europe/Paris [timezone_db] => Europe/Paris [date_type] => date ) ) ) [field_layout_news] => Array ( [und] => Array ( [0] => Array ( [value] => single ) ) ) [field_testo_opzionale_news] => Array ( ) [field_url_en_page] => Array ( ) [field_url_en_page_label] => Array ( ) [path] => Array ( [pathauto] => 1 ) [name] => francesca.forzan [picture] => 0 [data] => b:0; [num_revisions] => 1 [current_revision_id] => 451912 [is_current] => 1 [is_pending] => [revision_moderation] => [entity_view_prepared] => 1 ) [#items] => Array ( [0] => Array ( [fid] => 128174 [uid] => 2032 [filename] => n_fegato_medico.jpg [uri] => public://n_fegato_medico_0.jpg [filemime] => image/jpeg [filesize] => 19361 [status] => 1 [timestamp] => 1710146499 [type] => image [field_file_image_alt_text] => Array ( ) [field_file_image_title_text] => Array ( ) [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2048 ) ) ) [metadata] => Array ( [height] => 227 [width] => 677 ) [height] => 227 [width] => 677 [alt] => liver [title] => ) ) [#formatter] => image [0] => Array ( [#theme] => image_formatter [#item] => Array ( [fid] => 128174 [uid] => 2032 [filename] => n_fegato_medico.jpg [uri] => public://n_fegato_medico_0.jpg [filemime] => image/jpeg [filesize] => 19361 [status] => 1 [timestamp] => 1710146499 [type] => image [field_file_image_alt_text] => Array ( ) [field_file_image_title_text] => Array ( ) [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2048 ) ) ) [metadata] => Array ( [height] => 227 [width] => 677 ) [height] => 227 [width] => 677 [alt] => liver [title] => ) [#image_style] => [#path] => ) ) [field_abstract_news] => Array ( [#theme] => field [#weight] => 0 [#title] => Abstract [#access] => 1 [#label_display] => above [#view_mode] => teaser [#language] => und [#field_name] => field_abstract_news [#field_type] => text_long [#field_translatable] => 0 [#entity_type] => node [#bundle] => box_lancio_news [#object] => stdClass Object ( [vid] => 451912 [uid] => 2032 [title] => LIVERAIM - Developing a European Screening Platform for Liver Disease [log] => [status] => 1 [comment] => 0 [promote] => 1 [sticky] => 0 [nid] => 108433 [type] => box_lancio_news [language] => it [created] => 1710146499 [changed] => 1710146499 [tnid] => 0 [translate] => 0 [revision_timestamp] => 1710146499 [revision_uid] => 2032 [body] => Array ( [und] => Array ( [0] => Array ( [value] =>

LIVERAIM, a European research project that includes researchers from the University of Padua and its Teaching Hospital aims to improve the life and health of those suffering from liver diseases thanks to the start of the largest study carried out in this field.

Prof Paolo Angeli of the Department of Medicine at the University of Padua and Chief of the Unit of Internal Medicine and Hepatology at the University Teaching Hospital of Padua explains, “Liver cirrhosis and liver cancer are common and responsible for high morbidity, impaired quality of life, major costs for healthcare systems, and causing 300K deaths per year in Europe. Liver disease often progresses asymptomatically, until serious symptoms and complications occur. Unfortunately, at this advanced stage, treatment options are limited and liver transplantation is often the option. However, if detected early during the fibrosis stage, its progression can be prevented through effective interventions.”

Prof Salvatore Silvio Piano of the Department of Medicine at the University of Padua and local coordinator of the project comments, “The absence of an effective screening program represents a significant barrier to the early identification of these pathologies. While we have been successfully conducting liver disease screening in the Veneto region through the non-invasive test called Fibroscan, this method is only available at special clinics and centers.  If we want to promote a large-scale population screening, we must include general practitioners by providing them with tools such as a blood test to accurately identify individuals at risk of liver disease who may require in depth evaluations.”

With total funding of over 20M euros as part of the Innovation Health Initiative, the Joint Undertaking European LIVERAIM Project will see approximately 1,800,000 euros allocated to the University of Padua and its University Hospital.

LIVERAIM will design and validate a screening platform with biomarkers for population screening to use across Europe. The objective is to identify liver disease early and apply personalized therapeutic interventions.

[summary] => [format] => 2 [safe_value] =>

LIVERAIM, a European research project that includes researchers from the University of Padua and its Teaching Hospital aims to improve the life and health of those suffering from liver diseases thanks to the start of the largest study carried out in this field.

Prof Paolo Angeli of the Department of Medicine at the University of Padua and Chief of the Unit of Internal Medicine and Hepatology at the University Teaching Hospital of Padua explains, “Liver cirrhosis and liver cancer are common and responsible for high morbidity, impaired quality of life, major costs for healthcare systems, and causing 300K deaths per year in Europe. Liver disease often progresses asymptomatically, until serious symptoms and complications occur. Unfortunately, at this advanced stage, treatment options are limited and liver transplantation is often the option. However, if detected early during the fibrosis stage, its progression can be prevented through effective interventions.”

Prof Salvatore Silvio Piano of the Department of Medicine at the University of Padua and local coordinator of the project comments, “The absence of an effective screening program represents a significant barrier to the early identification of these pathologies. While we have been successfully conducting liver disease screening in the Veneto region through the non-invasive test called Fibroscan, this method is only available at special clinics and centers.  If we want to promote a large-scale population screening, we must include general practitioners by providing them with tools such as a blood test to accurately identify individuals at risk of liver disease who may require in depth evaluations.”

With total funding of over 20M euros as part of the Innovation Health Initiative, the Joint Undertaking European LIVERAIM Project will see approximately 1,800,000 euros allocated to the University of Padua and its University Hospital.

LIVERAIM will design and validate a screening platform with biomarkers for population screening to use across Europe. The objective is to identify liver disease early and apply personalized therapeutic interventions.

[safe_summary] => ) ) ) [field_date_box_lancio_news] => Array ( [und] => Array ( [0] => Array ( [value] => 2024-03-11T00:00:00 [timezone] => Europe/Paris [timezone_db] => Europe/Paris [date_type] => date ) ) ) [field_etichetta_box_lancio_news] => Array ( ) [field_img_box_lancio_news] => Array ( [und] => Array ( [0] => Array ( [fid] => 128174 [uid] => 2032 [filename] => n_fegato_medico.jpg [uri] => public://n_fegato_medico_0.jpg [filemime] => image/jpeg [filesize] => 19361 [status] => 1 [timestamp] => 1710146499 [type] => image [field_file_image_alt_text] => Array ( ) [field_file_image_title_text] => Array ( ) [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2048 ) ) ) [metadata] => Array ( [height] => 227 [width] => 677 ) [height] => 227 [width] => 677 [alt] => liver [title] => ) ) ) [field_link_alla_news] => Array ( ) [field_link_esterno_news] => Array ( [und] => Array ( [0] => Array ( [value] => [format] => [safe_value] => ) ) ) [field_pagina_associata] => Array ( ) [field_link_etichetta] => Array ( ) [field_abstract_news] => Array ( [und] => Array ( [0] => Array ( [value] => The Unipd research for early detection of liver disease will be funded with approximately 1,800,000 euros [format] => [safe_value] => The Unipd research for early detection of liver disease will be funded with approximately 1,800,000 euros ) ) ) [field_allegato_news] => Array ( ) [field_categorie_news] => Array ( [und] => Array ( [0] => Array ( [tid] => 2261 ) [1] => Array ( [tid] => 2296 ) ) ) [field_pub_date] => Array ( [und] => Array ( [0] => Array ( [value] => 2024-03-11T00:00:00 [value2] => 2025-03-11T00:00:00 [timezone] => Europe/Paris [timezone_db] => Europe/Paris [date_type] => date ) ) ) [field_layout_news] => Array ( [und] => Array ( [0] => Array ( [value] => single ) ) ) [field_testo_opzionale_news] => Array ( ) [field_url_en_page] => Array ( ) [field_url_en_page_label] => Array ( ) [path] => Array ( [pathauto] => 1 ) [name] => francesca.forzan [picture] => 0 [data] => b:0; [num_revisions] => 1 [current_revision_id] => 451912 [is_current] => 1 [is_pending] => [revision_moderation] => [entity_view_prepared] => 1 ) [#items] => Array ( [0] => Array ( [value] => The Unipd research for early detection of liver disease will be funded with approximately 1,800,000 euros [format] => [safe_value] => The Unipd research for early detection of liver disease will be funded with approximately 1,800,000 euros ) ) [#formatter] => text_default [0] => Array ( [#markup] => The Unipd research for early detection of liver disease will be funded with approximately 1,800,000 euros ) ) [links] => Array ( [#theme] => links__node [#pre_render] => Array ( [0] => drupal_pre_render_links ) [#attributes] => Array ( [class] => Array ( [0] => links [1] => inline ) ) [node] => Array ( [#theme] => links__node__node [#links] => Array ( [node-readmore] => Array ( [title] => Read more about LIVERAIM - Developing a European Screening Platform for Liver Disease [href] => node/108433 [html] => 1 [attributes] => Array ( [rel] => tag [title] => LIVERAIM - Developing a European Screening Platform for Liver Disease ) ) ) [#attributes] => Array ( [class] => Array ( [0] => links [1] => inline ) ) ) ) [field_date_box_lancio_news] => Array ( [#theme] => field [#weight] => 1 [#title] => Data [#access] => 1 [#label_display] => above [#view_mode] => teaser [#language] => und [#field_name] => field_date_box_lancio_news [#field_type] => date [#field_translatable] => 0 [#entity_type] => node [#bundle] => box_lancio_news [#object] => stdClass Object ( [vid] => 451912 [uid] => 2032 [title] => LIVERAIM - Developing a European Screening Platform for Liver Disease [log] => [status] => 1 [comment] => 0 [promote] => 1 [sticky] => 0 [nid] => 108433 [type] => box_lancio_news [language] => it [created] => 1710146499 [changed] => 1710146499 [tnid] => 0 [translate] => 0 [revision_timestamp] => 1710146499 [revision_uid] => 2032 [body] => Array ( [und] => Array ( [0] => Array ( [value] =>

LIVERAIM, a European research project that includes researchers from the University of Padua and its Teaching Hospital aims to improve the life and health of those suffering from liver diseases thanks to the start of the largest study carried out in this field.

Prof Paolo Angeli of the Department of Medicine at the University of Padua and Chief of the Unit of Internal Medicine and Hepatology at the University Teaching Hospital of Padua explains, “Liver cirrhosis and liver cancer are common and responsible for high morbidity, impaired quality of life, major costs for healthcare systems, and causing 300K deaths per year in Europe. Liver disease often progresses asymptomatically, until serious symptoms and complications occur. Unfortunately, at this advanced stage, treatment options are limited and liver transplantation is often the option. However, if detected early during the fibrosis stage, its progression can be prevented through effective interventions.”

Prof Salvatore Silvio Piano of the Department of Medicine at the University of Padua and local coordinator of the project comments, “The absence of an effective screening program represents a significant barrier to the early identification of these pathologies. While we have been successfully conducting liver disease screening in the Veneto region through the non-invasive test called Fibroscan, this method is only available at special clinics and centers.  If we want to promote a large-scale population screening, we must include general practitioners by providing them with tools such as a blood test to accurately identify individuals at risk of liver disease who may require in depth evaluations.”

With total funding of over 20M euros as part of the Innovation Health Initiative, the Joint Undertaking European LIVERAIM Project will see approximately 1,800,000 euros allocated to the University of Padua and its University Hospital.

LIVERAIM will design and validate a screening platform with biomarkers for population screening to use across Europe. The objective is to identify liver disease early and apply personalized therapeutic interventions.

[summary] => [format] => 2 [safe_value] =>

LIVERAIM, a European research project that includes researchers from the University of Padua and its Teaching Hospital aims to improve the life and health of those suffering from liver diseases thanks to the start of the largest study carried out in this field.

Prof Paolo Angeli of the Department of Medicine at the University of Padua and Chief of the Unit of Internal Medicine and Hepatology at the University Teaching Hospital of Padua explains, “Liver cirrhosis and liver cancer are common and responsible for high morbidity, impaired quality of life, major costs for healthcare systems, and causing 300K deaths per year in Europe. Liver disease often progresses asymptomatically, until serious symptoms and complications occur. Unfortunately, at this advanced stage, treatment options are limited and liver transplantation is often the option. However, if detected early during the fibrosis stage, its progression can be prevented through effective interventions.”

Prof Salvatore Silvio Piano of the Department of Medicine at the University of Padua and local coordinator of the project comments, “The absence of an effective screening program represents a significant barrier to the early identification of these pathologies. While we have been successfully conducting liver disease screening in the Veneto region through the non-invasive test called Fibroscan, this method is only available at special clinics and centers.  If we want to promote a large-scale population screening, we must include general practitioners by providing them with tools such as a blood test to accurately identify individuals at risk of liver disease who may require in depth evaluations.”

With total funding of over 20M euros as part of the Innovation Health Initiative, the Joint Undertaking European LIVERAIM Project will see approximately 1,800,000 euros allocated to the University of Padua and its University Hospital.

LIVERAIM will design and validate a screening platform with biomarkers for population screening to use across Europe. The objective is to identify liver disease early and apply personalized therapeutic interventions.

[safe_summary] => ) ) ) [field_date_box_lancio_news] => Array ( [und] => Array ( [0] => Array ( [value] => 2024-03-11T00:00:00 [timezone] => Europe/Paris [timezone_db] => Europe/Paris [date_type] => date ) ) ) [field_etichetta_box_lancio_news] => Array ( ) [field_img_box_lancio_news] => Array ( [und] => Array ( [0] => Array ( [fid] => 128174 [uid] => 2032 [filename] => n_fegato_medico.jpg [uri] => public://n_fegato_medico_0.jpg [filemime] => image/jpeg [filesize] => 19361 [status] => 1 [timestamp] => 1710146499 [type] => image [field_file_image_alt_text] => Array ( ) [field_file_image_title_text] => Array ( ) [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2048 ) ) ) [metadata] => Array ( [height] => 227 [width] => 677 ) [height] => 227 [width] => 677 [alt] => liver [title] => ) ) ) [field_link_alla_news] => Array ( ) [field_link_esterno_news] => Array ( [und] => Array ( [0] => Array ( [value] => [format] => [safe_value] => ) ) ) [field_pagina_associata] => Array ( ) [field_link_etichetta] => Array ( ) [field_abstract_news] => Array ( [und] => Array ( [0] => Array ( [value] => The Unipd research for early detection of liver disease will be funded with approximately 1,800,000 euros [format] => [safe_value] => The Unipd research for early detection of liver disease will be funded with approximately 1,800,000 euros ) ) ) [field_allegato_news] => Array ( ) [field_categorie_news] => Array ( [und] => Array ( [0] => Array ( [tid] => 2261 ) [1] => Array ( [tid] => 2296 ) ) ) [field_pub_date] => Array ( [und] => Array ( [0] => Array ( [value] => 2024-03-11T00:00:00 [value2] => 2025-03-11T00:00:00 [timezone] => Europe/Paris [timezone_db] => Europe/Paris [date_type] => date ) ) ) [field_layout_news] => Array ( [und] => Array ( [0] => Array ( [value] => single ) ) ) [field_testo_opzionale_news] => Array ( ) [field_url_en_page] => Array ( ) [field_url_en_page_label] => Array ( ) [path] => Array ( [pathauto] => 1 ) [name] => francesca.forzan [picture] => 0 [data] => b:0; [num_revisions] => 1 [current_revision_id] => 451912 [is_current] => 1 [is_pending] => [revision_moderation] => [entity_view_prepared] => 1 ) [#items] => Array ( [0] => Array ( [value] => 2024-03-11T00:00:00 [timezone] => Europe/Paris [timezone_db] => Europe/Paris [date_type] => date ) ) [#formatter] => date_default [0] => Array ( [#markup] => Lun, 11/03/2024 ) ) )

Pagine